Ref. No.: F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: edprmsc@nic.in

E-BID FOR THE RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS

(Two Years RC ending on 31.08.2024)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	**16.08.2022 & 6.00 PM**
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	**17.08.2022 & 11.00 AM**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in
CIN:U24232RJ2011SGC035067 E-mail : edprmsc@nic.in

Ref. No.: F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

Notice Inviting E-Bids

e-bids for rate contract cum empanelment for following items are invited from eligible bidders as detaited below:-

S.No	Item Name /Description	Ref.No	UBN	Estimated Value Rs. in Crore	Time & Last date for bid submission
1.	Analysis of Drugs & Medicine	F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022	MSC2223SLRC00044	7.13	Upto 6.00 P.M. on 16.08.2022

Other particulars of the bids may be visited on the procurement portal http://eproc.rajasthan.gov.in , http://sppp.rajasthan.gov.in and www.rmsc.health.rajasthan.gov.in and may be downloaded from there.

Executive Director (Procurement)
RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

e-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS

(Rate contract for two years ending on 31.08.2024)

Bid Reference	**:**	F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :- 27.07.2022
Pre- bid conference	**:**	**29.07.2022 at 12.30 P.M.**
Date and time for downloading bid document	**:**	**27.07.2022 from 06.00 PM**
Last date and time of submission of online bids	**:**	**16.08.2022 at 6.00 PM**
Date and time of opening of Online technical bids	**:**	**17.08.2022 at 11.00 PM**
Cost of the Bid Document	**:**	**Rs. 2360/- (Including GST@ 18%)**
RISL Processing Fees	**:**	**Rs. 1180/- (Including GST @ 18%)**
Bid Security	**:**	**Rs. 20000/-**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN

E-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Rate contract for two years ending on 31.08.2024)

"CONFIDENTIALITY IS THE ESSENCE OF THIS BID"

1. **LAST DATE FOR RECEIPT OF BIDS, BID FORM FEES, BID SECURITY & RISL PROCESSING FEES**

a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Shall Be Received Till 06.00 PM on 16.08.2022 By The Rajasthan Medical Services Corporation Ltd, For The Rate contract cum Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Rate contract for two years ending on **31.08.2024**) in English language. Proposal received after the closing date and time shall not be considered.

b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid Security deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.

c) The e-Bids will be received on web-portal of e-procurement of GoR i.e. http://eproc.rajasthan.gov.in. Every Bidder will be required to pay the Bid form fee Rs. 2360/- (Including GST@ 18%) for downloaded forms from the website, Bid Security as applicable in Bid condition no. **6** and processing fee of Rs. 1180/- (Including GST@ 18%) of R.I.S.L. through three separate prescribed challans (***format enclosed in Annexure- I)*** in any branch of the Punjab National Bank into Account no. 2246002100024414 throughout the country upto 16.08.2022 or through D.D. / Bankers Cheque in favour of M.D. RMSCL (tender fees and Bid Security) and MD, RISL (tender processing fees) physically in the office of RMSCL by 6.00 PM on 16.08.2022 The bidders shall submit/upload scanned copy of all the challans in Technical Bid**.** Bids will be opened only after ensuring receipt of Bid fees along with processing fees and Bid Secrity. **In the absence of Bid fees, processing fees and Bid security the Bids shall be rejected and shall not be opened.**

2. **<u>Eligibility Criteria for Empanelment :-</u>**

(1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of **drugs/chemicals or food** items and the lab shall be entitled for empanelment for the categories of items for which lab has bidded and having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.

(2) ***The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department*** **and NABL accreditation with proper scope of accreditation to undertake testing of drugs, surgical and sutures.**

(3) The laboratory should have an average annual turnover of **not** less than **Rs. 50 Lakh** for past preceding three years **(**2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22**).**

Only audited accounts would be considered provisional accounts would not be considered in any case.

(4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of drugs for at least three government institutions/corporation/reputed manufacturers of drug formulations.

(5) The lab should not stand banned / debarred or blacklisted by any State **or** Central Government or its Organizations or its procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.

(i) Bid rejection

(ii) Bid Security forfeiture

(iii) Agreement rejection

(iv) Performance Security forfeiture

(v) Blacklisting

(6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and

conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

a. Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be analyzed tested as at Annexure-VII).

b. The bidders shall submit/upload in Technical Bid scanned copies of all the challans / DD/ BC of deposits of Bid form fees, RISL processing fee and Bid Security Money.

c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.

d. **Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.**

e. Documentary evidence of having analysed Drugs, chemicals, foods and other items for last three years with a statement in the proforma as given in Annexure III.

f. Attested copy of certificate of GST registration.

g. GST return 31.03.2022 or latest Months

h. Non- Conviction Certificate by the State Licensing Authority/ competent authority.

i. Annual turnover statement for 3 year i.e. **(**2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22**)** certified by the practicing Chartered Accountant with UDIN No.

j. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. **(** 2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22**)** duly audited or certified by the practicing Chartered Accountant. No provisional balance sheet or Profit and Loss account would be entertained.

k. The following information in the form given in Annexure IV (a) to IV (d).

   a) The list of permanent technical qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.

b) The list of sophisticated instruments available in the laboratory.

c) Micro Biological facilities available in the laboratory.

d. List of Reference Samples along with their date of procurement and quantities.

e. In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as "Not of the Standard Quality".

l. A declaration in the proforma given in Annexure V duly signed and Notarized.

m. Details of Laboratory in Annexure – VI.

n. A copy of PAN issued by Income Tax Department.

o. Documentary evidence for the constitution of the company / concern.

p. At any time prior to opening of price bid, RMSC either at their own initiate or in response to clarification requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be uploaded on e-Proc site and will be part of the tender.

q. A bidder has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 PRICE BID:

The price bid shall also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bid is liable to be rejected for the particular item. Bidders are allowed to enter the bidder name and values only**. **The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled clarifications on prices or rebates shall not be accepted.**

5 OPENING OF TECHNICAL BID AND FINANCIAL BID EVALUATION

The technical bids would be opened on scheduled date and time on eproc website i.e. https://eproc.rajasthan.gov.in. After technical evaluation physical inspection of the laboratories may be carried out by the designated team. Thereafter financial bids would be opened of those bidders who are found

finally responsive on technical criteria. The acceptable rates for analysis will be decided and communicated accordingly.

6 BID SECURITY

The Bid Security Money Deposit shall be Rs. 20,000/- (Rs Twenty Thousand only) The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 16.08.2022 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on 16.08.2022 Bid Security Deposit in any other form will not be accepted

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails to sign the contract agreement or fails to furnish the security deposit within the stipulated time.

Government undertaking PSU are exempted from Bid Security deposition on producing the certificate issued by the competent authority.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. *The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test*. ***However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ.***
3. The rates quoted should be exclusive of taxes, though the applicable taxes are to be mentioned separately.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the rate contract period including extensions, if any given.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test to any other laboratory.
7. RMSCL shall have the right to cause inspection of the laboratory by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
8. Conditional tender will not be accepted and rejected immediately.
9. ***GST at applicable rate should be mentioned by the bidder where evere applicable.***

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria specified in bid document.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bids depending on the volume of analytical work.

9. AGREEMENT

1. **The agreement with empanelled laboratories shall remain valid up to 31.08.2024. If Required period of contract can be extended upto 3 months on same rate, terms and condition without any prior consent of the bidder and shall be binding on approved bidder.**
2. RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value **Rs. 500 /-** (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL. (Annexure IX)
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any other person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or emailed on its email address or left at the premises, places of business or abode.

10. <u>PERFORMANCE SECURITY</u>

1. The successful Bidders shall be required to pay a Performance Security of **Rs. 50,000/-** (Rs Fifty Thousand only) ***in the form of demand draft*** at the time of

execution of the agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:

i. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)

ii. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.

b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.

c) Mentioning only "COMPLIES" or "PASSES" in the result column of the report would be treated as incomplete report, if the result has some numerical value.

d) Every test report must have remarks either as "Standard Quality" or "Not of Standard Quality". Any ambiguity/cutting in reports will not be accepted (clear mention of "standard quality or not of standard quality" should be stated in bold letters and crossing/cutting of one of these will not be accepted).

e) Reports should be in A4 size (8.27" X 11.69") paper of good quality.

f) Report should be issued on form 39 A and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.

g) Reports should be attached along with Spectra / Chromatography data

sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.

2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / e-mail and the report should be sent along with protocol.
3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.
4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.
6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.
7. The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.

8. It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYM ENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.
4. **GST shall be applicable as per prevailing rates notified by the Government.**

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and deposit security amount within the time specified or withdraws the BID after intimation of the acceptance of the BID or owing to any other reasons, is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money amount deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final and binding.
2. After entering into Rate contract, if the laboratory does not as per the terms and conditions, it may be disqualified to participate in the BID for the period as decided by RMSCL.
3. To assess the correctness of the test results being given by the Empanelled laboratories, samples at random, would also be sent to the Government Analyst for testing and if any variation is found the result would be informed to empanelled laboratories. If there is any gross variation in the analytical reports furnished by the empanelled laboratories (either pass or fail) with Government

Lab for 3 times in assay test and 4 times for any other specification, in a year, the empanelled laboratory shall be considered for blacklisting for a period as considered proper after following the due process.

4. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.

5. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate, the empanelment of any laboratory either wholly or in part at one month's notice without assigning any reasons. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
6. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
7. (i)If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance it shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of ***furnishing the test report***.

   (ii)The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

   (iii)**Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of ***testing charges*** which the Bidder has failed to submit:-

   (a) Delay upto one fourth period of the prescribed testing period; 2.5%

(b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

(c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

iv. If, at any time during the continuance of this Agreement, the ***laboratory*** has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the ***RMSCL*** purely at his discretion for such period as may be considered reasonable. No further representation from the ***laboratory*** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

The Designation and address of the First Appellate Authority is MD, NRHM.

The Designation and address of the Second Appellate Authority is Secretary to Government, Medical & Health and Family Welfare, Govt. of Rajasthan.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of

receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of empanelment;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a empanelment process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a empanelment process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.+

19. APPLICABILITY OF RULES

Besides above conditions all the provisions of RTPP Act 2012 & RTPP Rules 2013 shall be applicable.

Managing Director
Rajasthan Medical Services Corporation

Annexure - 1

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

Customer Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

ANNEXURE- II
Ref. Clause No. 2 (3), 3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover of M/s._____ for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Lacs (Rs)
1	2018-19	
2	2019-20	
3	2020-21	
Total		**Rs.** **Lacs**
Average turnover per annual		**Rs.** **Lacs**

Or

S.No.	Years	Turnover in Lacs (Rs)
1	2019-20	
2	2020-21	
3	2021-22	
Total		**Rs.** **Lacs**
Average turnover per annual		**Rs.** **Lacs**

Date:

Siganture of Auditor/
Chartered Accountant

Seal:
UDIN No.

(Name in Capital)

ANNEXURE III
Ref. Clause No: 3 (e)

PROFORMA FOR PERFORMANCE STATE MENT
(for a period of last 3 years)

Name of the Laboratory : _____

Address:_____

_____

_____

Types of Samples Analysed No. of Samples Analysed during

(2018-19, 2019-20 and 2020-21 or 2019-20, 2020-21, 2021-22

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Specify)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :
Date :
Name of the Lab :
Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTM ENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature :

Date :

Nam e of the Lab :

Office Seal :

ANNEXURE – IV (b)
Ref. Clause No: 3(j) (b)

LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS AVAILABLE IN THE LAB

S.No.	Name of the Equipment Instruments / Apparatus	Make & Description	Date of Installation	Date of last Validation	Approved for testing of drugs from State licensing Authority since……..

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

LISTOF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMETN AND QUANTITIES

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O_____, Age_____, resident of_____, am proprietor /Partner/Director having our office at_____ and the approved drug testing laboratory at_____do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (Rate contract for two years ending on **31.08.2024**) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drugs/surgicals & sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drugs/surgical & sutures have been obtained on Form 37 bearing No._____which is valid/renewed up to_____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

   Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

That I/We have carefully read all the conditions of bid in Ref. No.**:** F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

6. That we have testing facilities as per testing parameters mentioned in Annexure VII and quoted for products as given below:-

Sr No.	**Quoted item Code No. (as per mention in Annexure-VII)**
1.	**For Example** NRD-1
2.	
3.	

7. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Rate contract for two years ending on **31.08.2024**) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.

8. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
    a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
    b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
    c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
    d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
    e. l/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;

9. Our complete address for communication with phone no.:- ----------

---

---

10. E mail address :- ----------

11. Bank detail for e banking :-

    Name of account holder ……

    Full name of Bank with Branch ……

    A/c no. with full digits……..

    IFSC code ……..

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I……..S/o……(Designation)…….

Affirm on oath that the contents/information from para 1 to 10 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the Bid Security deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC

ANNEXURE – VI
Ref.Clause No: 3 (l)

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :

   Phone No (landline) :

   Fax :

   E-mail :

2. Other Branches & their Address (if any) :

3. Whether the firm has it own manufacturing unit? :

   If yes give details of address, license number etc.

4. Date of Inception :

5. Approval No. & Date :

6. Issued by :

7. Valid up to :

8. Schedule L-1 certificate its no. and date of issue (GLP) :

   or

9. (i) NABL Accreditation no. & date
   (ii) Scope of Accreditation
   (iii) Its validity.

10. Name of the authorized signatory :

11. Specimen Signature of the authorized Signatory :

12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

NOTE:-

- **Bidders have to mention quoted item code in annexure V for which have testing facility as per testing parameters.**
- **Bidders are advised to carefully go through the testing parameters and in case of any suggestion for change in parameters it may be submitted at least one day in advance to pre-bid meeting. No suggestion for change in parameters would be entertained after pre-bid meeting.**
- **Test parameters to be carried out for analysis of each item are mentioned below:-**

S.No	Drug Code	Item Name		Test parameters to be carried out
1.	NRD-4	Glucosamine 750mg and Methylsulfonylmethane 200mg Capsule/Tablet	1	Description
			2	Identification (by HPLC)
				Glucosamine
				Methylsulfonylmethane
			3	Average net content
			4	Disintegration or Dissolution (by HPLC) Glucosamine HCL/Methylsulfonylmethane
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Glucosamine
				Methylsulfonylmethane
2.	NRD-5	Racecadotril Cap. IP 100mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Dissolution (by HPLC)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
3.	NRD-6	Rabeprazole 20mg Enteric Coated +Levosulpiride 75 mg SR Cap.	1	Description
			2	Identification (by HPLC)
				Rabeprazole
				Levosulpiride
			3	Average net content
			4	Dissolution (by HPLC)
				Rabeprazole
				Acid Medium
				Phosphate Buffer
				Levosulpiride
				1st Point
				2nd Point
				3rd Point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Rabeprazole
				Levosulpiride
4.	NRD-7	Acitretin 10 mg Cap. IP	1	Description
			2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
5.	NRD-8	Acitretin 25 mg Cap. IP	1	Description
			2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of Weight

			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
6.	NRD-9	Alectinib 150 mg Cap.	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
7.	NRD-11	Anti-Oxidants Cap. (Beta Carotene-10 mg,Vit-E 25mg,Vit-C 100 mg,Copper 1.5 mg,Managanese 1.5 mg,Zinc 7.5 mg,Selenium 150 microgram)	1	Description
			2	Identification
			3	Beta Carotene (by UV)
			4	Vitamin E (by UV)
			5	Vitamin C (by Chemical)
			6	Copper (by ICP MS)
			7	Manganese (by ICP MS)
			8	Zinc (by ICP MS)
			9	Selenium (by ICP MS)
			10	Average Fill
			11	Uniformity of weight
			12	Disintegration time
			13	Contents of Packaged Dosage Forms
			14	**Assay:**
			15	Beta Carotene (by UV)
			16	Vitamin E (by UV)
			17	Vitamin C (byChemical)
			18	Copper (by ICP MS)
			19	Manganese (by ICP MS)
			20	Zinc (by ICP MS)
			21	Selenium (by ICP MS)
8.	NRD-12	Aprepitant Cap. IP 125/80mg Capsule/Tablet Kit (each kit contains 1 capsule/Tablet of 125mg & 2 capsule/Tablet of 80mg)	1	Description
			2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
9.	NRD-14	Calcium Dobesilate Cap. 500MG	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
10.	NRD-18	Ceritinib Cap. 150mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
11.	NRD-19	Clomipramine Cap./Tab. IP 25 mg	1	Description
			2	Identification (by IR)
			3	Average net content
			4	Related substances (by HPLC)
			5	Disintegration Time
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
12.	NRD-20	Cyclosporine Cap. IP 100 mg	1	Description
			2	Identification (by HPLC)
				Water
			3	Average net content
			5	Dissolution (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms

			8	Assay (by HPLC)
13.	NRD-21	Dacarbazine Inj. USP 200 mg (DTIC)	1	Description
			2	Identification A by UV
			3	Identification B by HPLC
				Identification c
			4	pH
			5	5-Aminoimidazole-4-carboxamide hydrochloride by HPLC
			6	Related Substances (by HPLC)
			7	Bacterial Endotoxins
			8	Sterlity
			9	Particulate Matter
			10	Assay by UV
14.	NRD-22	Danazol cap. IP 100mg	1	Description
			2	Identification A (by IR)
			3	Average net content
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
15.	NRD-24	Formetrol 12mcg + Budesonide 400 mcg. Powder for Inhalation	1	Description
			2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Acceptance Criteria
			4	Average Fill
				Disintegration Time
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
				Formetrol
				Budesonide
			9	**Microbial Contamination**
				Total aerobic count
				Total fungal count
				E. coli
16.	NRD-25	Indacaterol and Glycopyronium inhalation powder 110/50 mcg Hard Capsules	1	Description
			2	Identification (by HPLC)
				Indacaterol
				Glycopyronium
			3	Acceptance Criteria
			4	Average Fill
				Disintegration Time
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
				Indacaterol
				Glycopyronium
			9	**Microbial Contamination**
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
17.	NRD-26	Isotretinoin Cap. IP 10mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average net content

			5	Uniformity of Content (by UV)
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
18.	NRD-27	Isotretinoin Cap. IP 20 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average net content
			5	Uniformity of Content (by UV)
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
19.	NRD-28	Lomustine Capsule BP 40 mg	1	Description
			2	Identification A (IR)
			3	Identification B (Melting Point)
			4	Related Substances(by TLC)
			5	Average net content
			6	Uniformity of weight
			7	Disintegration time
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
20.	NRD-29	Minocycline Capsule/Tablet BP 100mg.	1	Description
			2	Identification (IR)
			3	Related Substances(by HPLC)
			4	Average net content
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	Assay (by HPLC)
21.	NRD-30	Mycophenolate Mofetil Cap. /Tablet IP 500MG	1	Description
			2	Identification A (by UV)
				Identification A (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	Dissolution (by UV)
				Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
22.	NRD-31	Netupitant + Palonosetron 300 mg + 0.5 mg Cap./Tablet	1	Description
			2	Identification (by HPLC)
				Netupitant
				Palonosetron
			3	Average net content
			4	Disintegration or Dissolution (by HPLC) Netupitant HCL/Palonosetron
			5	Uniformity of Weight
				Uniformity of Content(by HPLC) Palonosetron 0.5mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Netupitant
				Palonosetron
23.	NRD-32	Ramipril Cap./Tablet IP 5 mg	1	Description
			2	Identification (by IR)
			3	Average net Content
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)

			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
24.	NRD-33	Rucaparib Cap. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
25.	NRD-34	Rucaparib Cap. 300 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
26.	NRD-35	Silodosin Cap./Tablet 4 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
27.	NRD-36	Silodosin Cap./Tablet 8 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
28.	NRD-37	Temozolamide Cap. IP 250 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	Disintegration test
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
29.	NRD-38	Vitamin A Cap. IP 25000 IU	1	Description
			2	Identification A (by TLC)
				Identification B (by Chemical)
			3	Average net content
			4	Uniformity of weight
			5	Disintegration test
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
30.	NRD-39	Carbolic Acid Crystal 100gm		As per STP of firm
31.	NRD-40	Carbolic Acid Crystal 400gm		As per STP of firm
32.	NRD-46	Amorolfine 0.25% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
33.	NRD-47	Azelaic acid 20% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
34.	NRD-48	Benzoyl Peroxide Gel 2.5 % IP	1	Description
			2	Identification (by TLC)
			3	Related Substances (by HPLC)
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by Chemical)
35.	NRD-49	Desonide 0.05% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
36.	NRD-51	Glycolic Acid 6% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms

			4	**Assay:** (by HPLC)
37.	NRD-52	Hydrocortisone 1% Cream IP	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by TLC)
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
38.	NRD-53	Hydroquinone Cream USP 2%	1	Description
			2	Identification A (by TLC)
			3	Minimum Fill
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by UV)
39.	NRD-55	Luliconazole 1% Cream IP	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related Substances (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
40.	NRD-56	Mometasone 0.1 % Cream IP	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
41.	NRD-58	Neomycin Sulphate 0.5% Cream USP	1	Description
			2	Identification A (by TLC)
			3	Minimum Fill
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by Chemical)
42.	NRD-60	Adaplene (0.1% W/W) Gel	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
43.	NRD-62	Dextrose 5% with Sod.Chloride 0.9% Injection 500ml glass Bottle	1	Description
			2	Identification A (Chemical)
			3	Identification B (Chemical)
			4	pH
			5	5-Hydroxymethylfurfural and related substances (by UV)
			6	Particulate contamination (by particle counter)
			7	Extractable volume
			8	Bacterial endotoxins
			9	**Assay:**
			10	For sodium chloride (Chemical)
			11	For dextrose (by optical rotation)
			12	Sterility
44.	NRD-65 a	Salmetrol 50mcg+Fluticasone 500 mcg DPI IP	1	Description
			2	Identification (by HPLC)
				Salmetrol
				Fluticasone
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)
				Salmetrol
				Fluticasone

45.	NRD-65 b	Salmetrol 50mcg+Fluticasone powder for Inhalation IP 500 mcg	1	Description
			2	Identification (by HPLC)
				Salmetrol
				Fluticasone
			3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
				Salmetrol
				Fluticasone
			9	**Microbial Contamination**
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
46.	NRD-66	Budesonide 400 mcg DPI IP	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Average weight
			5	Epimer-A (by HPLC)
			6	Related Substances (by HPLC)
			7	Content of Active Ingredient delivered per actuation
			8	Uniformity of delivered dose
			9	Particle Size
			10	Number of deliveries per container
			11	leak test
			12	deposition of the emitted dose
			13	Contents of Packaged Dosage Forms
			14	**Assay:** (by HPLC)
47.	NRD-70	Levosalbutamol 100mcg+ Ipratropium Bromide 40mcg DPI	1	Description
			2	Identification (by HPLC)
				Glycopyrronium
				Formoterol
			3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
				Glycopyrronium
				Formoterol
			9	**Microbial Contamination**
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
48.	NRD-71	Diastase, Pepsin with simethicone 15ml Drop Each ml contains Diastase (1:1200) 33.33mg, Pepsin (1:3000) 5mg, Simethicone emulsion 40mg	1	Description
			2	Identification (by HPLC)
				Diastase
				Pepsin
				simethicone
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Diastase

				Pepsin
				simethicone
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
49.	NRD-76	Hydroxyzine HCL Oral Solution IP 15 ml	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by TLC)
			4	pH
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
50.	NRD-77	Ambroxol drop 7.5mg/ml 15ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
51.	NRD-78	Anticold Drop (Each ml contains Paracetamol 125mg, Chlorpheniramine Maleate 1mg, Phenylephrine HCL 2.5mg) 15 ml	1	Description
			2	Identification (by HPLC)
				Paracetamol
				Chlorpheniramine Maleate
				Phenylephrine HCL
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Paracetamol
				Chlorpheniramine Maleate
				Phenylephrine HCL
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
52.	NRD-81	Ferrous Ascorbate and Folic Acid Drops 15 ml each ml contains Ferrous Ascorbate 10mg and Folic Acid 100mcg)	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	Identification C
			5	pH
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	For Ferrous Iron (by Chemical)
			9	Folic Acid (by HPLC)
			10	Identification of colour
			11	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
				Staphylococcus Aureus
				Pseudomonas Aeruginosa
				Salmonella
53.	NRD-83	Vitamin – E Oral Drop 50mg/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH

			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
54.	NRD-84	Vitamin D3 Oral Drop 400IU/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
55.	NRD-85	Vitamin D3 Oral Drop 800IU/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
56.	NRD-86	Cefpodoxime Oral Suspension IP 25mg/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			6	Assay (by HPLC)
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
57.	NRD-87	Lactulose Enema 20%`	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Net content
			5	Assay (by HPLC)
			6	Clarity of colour of solution
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	1	Description
			2	Identification (by UV)
			3	pH
			4	Particle Size
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
			7	Sterility
59.	NRD-95	Olaptadine 0.1% & Ketorolac 0.4% Opthalmic Suspension	1	Description
			2	Identification (by HPLC)
				Olaptadine
				Ketorolac
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Olaptadine
				Ketorolac
			6	Sterility
60.	NRD-98	Brinozolamide 1% w/v +Brimonidine Tartarate 0.2% w/v Opthalmic Suspension	1	Description
			2	Identification (by HPLC)
				Brinozolamide
				Brimonidine

			3	pH
			4	Contents of Packaged Dosage Forms
				Particle Size
			5	**Assay:** (by HPLC)
				Brinozolamide
				Brimonidine
			6	Sterility
61.	NRD-99	Chlorpheniramine maleate 0.01% +Carboxymethylcellulose 0.02% +Nephazoline 0.1% Eye Drop	1	Description
			2	Identification (by HPLC)
				Chlorpheniramine
				Carboxymethylcellulose
				Nephazoline
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Chlorpheniramine
				Carboxymethylcellulose
				Nephazoline
			6	Sterility
62.	NRD-100	Cyclopentolate 1% Eye Drop IP	1	Description
			2	Identification (by IR)
			3	pH
			4	Related substances (by TLC)
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
			7	Sterility
63.	NRD-101	Dorzolamide 2% Eye Drop IP	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
			7	Sterility
64.	NRD-102	Flurometholone 0.1% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
65.	NRD-103	Gatifloxacin 0.30% +Prednisolone Acetate 1% Opthalmic Suspension	1	Description
			2	Identification (by HPLC)
				Gatifloxacin
				Prednisolone
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Particle Size
			6	**Assay:** (by HPLC)
				Gatifloxacin
				Prednisolone
			7	Sterility
66.	NRD-104	HPMC 0.3% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
67.	NRD-105	Itraconazole 1% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH

			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
68.	NRD-106	Loteprednol 0.25% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
69.	NRD-107	Moxifloxacin 0.5%+Ketorolac Tromethamine 0.5% Eye Drop	1	Description
			2	Identification (by HPLC)
				Moxifloxacin
				Ketorolac Tromethamine
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Moxifloxacin
				Ketorolac Tromethamine
			6	Sterility
70.	NRD-108	Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drop	1	Description
			2	Identification (by HPLC)
				Moxifloxacin
				Dexamethasone
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Moxifloxacin
				Dexamethasone
			6	Sterility
71.	NRD-109	Moxifloxacin 0.5% and Prednisolone 1% Opthalmic Solution	1	Description
			2	Identification (by HPLC)
				Moxifloxacin
				Prednisolone
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Moxifloxacin
				Prednisolone
			6	Sterility
72.	NRD-110	Nepafenac 0.1% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
			7	Sterility
73.	NRD-113	Prednisolone Sodium Phosphate Ear/Eye Drop BP 1%	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Identification C (by Chemical)
			5	Acidity and Alkanility
			6	Free Prednisolone (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
			9	Sterility
74.	NRD-114	Proparacaine Eye Drop USP 0.5% W/v	1	Description
			2	Identification (by chemical)
			3	pH
			4	Uniformity of dosage units
			5	**Assay:** (by HPLC)

			6	Sterility
75.	NRD-115	Sodium Chloride Eye Drop BP 5 %	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Contents of Packaged Dosage Forms
			5	Assay (by Chemical)
			6	Sterility
76.	NRD-117	Travapost 0.004% and Timolol 0.5% Eye Drop	1	Description
			2	Identification (by HPLC)
				Travapost
				Timolol
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Travapost
				Timolol
			6	Sterility
77.	NRD-118	Tropicamide 0.8% w/v+Phenylepherine HCL 5% w/v Eye Drop	1	Description
			2	Identification (by HPLC)
				Travapost
				Timolol
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Travapost
				Timolol
			6	Sterility
78.	NRD-119	Voriconazole 1% w/v (Lyophilized) 30mg Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
79.	NRD-120	Azithromycin Eye Ointment 1%	1	Description
			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
80.	NRD-121	Chloramphenicol Eye Ointment IP 0.5%	1	Description
			2	Identification A (by IR)
			3	Identification B (Chemical)
			4	Minimun fill
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
			7	Sterility
81.	NRD-123	Chloramphenicol 1% , Polymyxin B Sulphate 10000 units + Dexamethasone 0.1% Sodium phosphate Eye Ointment	1	Description
			2	Identification (by HPLC)
				Chloramphenicol
				Polymyxin B Sulphate
				Dexamethasone
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
				Chloramphenicol
				Polymycin
				Dexamethasone
			6	Particle Size
			7	Sterility
82.	NRD-124	Ganciclovir Eye Ointment 0.15%	1	Description

			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
83.	NRD-125	Itraconazole Eye Ointment 1%	1	Description
			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
84.	NRD-126	Moxifloxacin Eye Ointment 0.5%	1	Description
			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
85.	NRD-127	Sodium Chloride 6% Eye Ointment USP	1	Description
			2	Identification A (by Chemical)
			3	Identification B (Chemical)
			4	Particulate matter
			5	foreign matter
			6	Container content
			7	**Assay:** (by Chemical)
			8	Sterility
86.	NRD-128	Povidone iodine Gargle 0.5% w/v	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
87.	NRD-129	Gatifloxacin 0.3% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by HPLC)
			6	Sterility
88.	NRD-132	Glycine Irrigation Solution 1.5% 3LTR IP	1	Description
			2	Identification A (by IR)
				Identification B (by TLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Extractable Vollume
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by Chemical)
			10	Sterility
89.	NRD-139	Hydrogen 11% + Silver Nitrate .01% Solution		As per STP of firm
90.	NRD-141	Metoprolol Inj. IP 1mg/ml l vial	1	Description
			2	Identification B (by HPLC)
			3	Identification C (by HPLC)
			4	Identification D (by IR)
			5	pH
			6	Average net Content
			7	Uniformity Of weight
			8	Related substances (by HPLC)
			9	Extractable volume
			10	Particulate matter
			11	**Assay:** (by UV)
			12	Sterility
91.	NRD-143	Docetaxel Inj. IP 80 mg/4ml	1	Description
			2	Identification A (by HPLC)
			3	Related substances (by HPLC)

			4	Average net Content
			5	Uniformity Of weight
			6	Extractable volume
			7	Particulate matter
			8	**Assay:** (by HPLC)
			9	Sterility
92.	NRD-145	Sodium Chloride Inj. IP 3% 100ml	1	Description
			2	Identification (Chemical)
			3	Heavy metals
			4	pH
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
			8	**Assay:** Sodium chloride (Chemical)
			9	Sterility
93.	NRD-156	Artesunate Inj. IP 120 mg (Each Combo Pack contains Artesunate Injection 120 mg Vial, Sodium Bicarbonate Injection IP 5% w/v (2 ml ampoule), Sodium chloride Injection IP 0.9% w/v (10 ml ampoule)	1	Description
			2	Identification A (by IR)
				Identification B (by TLC)
			3	Average net content
			4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Bacterial endotoxins
			7	Water
			8	Clarity of solution test a and b
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
			B	**Sodium Bicarbonate Injection IP**
			1	Description
			2	Identification A
			3	Identification B
			4	pH
			5	Extractable volume
			6	Particulate matter
			7	Bacterial endotoxins
			8	Assay: Sodium bicarbonate
			9	Sterility
			C	**Sodium chloride Injection IP**
			1	Description
			2	Identification
			3	Heavy metals
			4	pH
			5	Extractable volume
			6	Bacterial endotoxins
			7	Particle Matter (Particle Counter)
			8	Assay: Sodium chloride
			9	Sterility
94.	NRD-160	Azacitidine Inj. 100mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
95.	NRD-161	Azithromycin Inj. 10 ml vial equaivelent to 500 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight

			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
96.	NRD-169	Caffeine Cirate Injection BP 20mg/ml	1	Description
			2	Identification A (TLC)
			3	Identification B (HPLC)
			4	Identification C (Chemical)
			5	Related Susbstances (by HPLC)
			6	Average net content
			7	Uniformity of Weight
			8	pH
			9	Particulate matter
			10	Extractable volume
			11	Impurity
			12	Assay(by HPLC)
			13	Sterility
97.	NRD-173	Carfilzomib Inj. 30 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
98.	NRD-174	Carfilzomib Inj. 60 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
99.	NRD-175	Carmustine Inj. IP 100 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Related Substances (by HPLC)
			10	Clarity of solution test a and b
			11	Particulate matter
			12	**Assay:** (by HPLC)
			13	Sterility
100.	NRD-176	Caspofungin Inj. 50 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
101.	NRD-177	Caspofungin Inj. 70 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b

			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
102.	NRD-178	Cefipime 1000MG + Tazobactum Inj. 125MG	1	Description
			2	Identification (by HPLC)
				Cefipime
				Tazobactum
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Cefipime
				Tazobactum
			10	Sterility
103.	NRD-179	Cefoperazone 1gm+Tazobactum Inj. 125mg	1	Description
			2	Identification (by HPLC)
				Cefipime
				Tazobactum
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Cefipime
				Tazobactum
			10	Sterility
104.	NRD-180	Cefoperazone Inj. IP 500mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay:** (by HPLC)
			12	Sterility
105.	NRD-181	Ceftazidime 1gm+Sulbactam Inj. 500 mg	1	Description
			2	Identification (by HPLC)
				Ceftazidime
				Sulbactam
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Ceftazidime
				Sulbactam
			10	Sterility
106.	NRD-182	Ceftazidime+ Avibactum Inj. 2gm+500mg	1	Description
			2	Identification (by HPLC)

				Ceftazidime
				Avibactum
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Ceftazidime
				Avibactum
			10	Sterility
107.	NRD-183	Ceftizoxime Inj. IP 1 Gm	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay:** (by HPLC)
			12	Sterility
108.	NRD-184	Ceftriaxone Inj. IP 125 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Identification C
			5	Appearance of solution
			6	pH
			7	Related substances (by HPLC)
			8	Bacterial endotoxins
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	**Assay:** (by HPLC)
			15	Sterility
109.	NRD-185	Ceftriaxone 1000mg +Salbactum 500mg + disodium EDTA 37mg Inj.	1	Description
			2	Identification (by HPLC)
				Ceftriaxone
				Salbactum
				disodium EDTA
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Ceftriaxone
				Salbactum
				disodium EDTA
			10	Sterility
110.	NRD-187	Ceftriaxone1000mg+ Tazobactom125mg Inj.	1	Description
			2	Identification (by HPLC)
				Ceftriaxone
				Tazobactom

			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	**Assay: (by HPLC)**
				Ceftriaxone
				Tazobactom
			10	Sterility
111.	NRD-188	Cefuroxime Inj. IP 1Gm	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Related substances (by HPLC)
			6	Bacterial endotoxins
			7	Water
			8	Average weight
			9	Uniformity of weight
			10	Particulate matter
			11	Clarity of solution A and B
			12	**Assay:** (by HPLC)
			13	Sterility
112.	NRD-189	Cetrorelix Acetate Inj. 0.25 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
113.	NRD-192	Chloramphenicol Sodium Succinate Inj. IP 1gm/vial	1	Description
			2	Identification A (by TLC)
			3	Identification B
			4	Identification C
			5	pH
			6	Specific optical rotation
			7	Free Chloramphenicol (by TLC)
			8	Bacterial endotoxins
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	**Assay:** (by UV)
			15	Sterility
114.	NRD-193	Cladrabine Inj. 10 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
115.	NRD-194	Clarithromycin for Infusion BP 500mg/vial	1	Description
			2	Identification A (by IR)
			3	pH
			4	Clarity of solution test a and b
			5	Particulate matter

			6	Average net content
			7	Uniformity of Weight
			8	Related Substances (by HPLC)
			9	Sterility
			10	Assay(by HPLC)
116.	NRD-199	Cytarabine Inj. IP 1000 mg	1	Description
			2	Identification (by IR)
			5	pH
			7	Related Substances (by TLC)
			8	Bacterial endotoxins
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	**Assay:** (by Titration)
			15	Sterility
117.	NRD-201	Dextrose Inj. IP 5% 500 ml Glass Bottle	1	Description
			2	Identification A
			3	Identification B (by optical rotation)
			4	pH
			5	5-Hydroxymethylfurfural and related substances (by UV)
			6	Heavy metals
			7	Particulate contamination (by particle counter)
			8	Extractable volume
			9	Bacterial endotoxins
			10	**Assay:** (by optical rotation)
			11	Sterility
118.	NRD-207	Decitabine Inj. 50 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
119.	NRD-209	Degarelix Inj.80 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
120.	NRD-210	Degarelix Inj. 120 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
121.	NRD-220	Docetaxel Inj. IP 120 mg	1	Description
			2	Identification A (by HPLC)
			3	Related substances (by HPLC)
			4	Average net Content
			5	Uniformity Of weight
			6	Extractable volume

			7	Particulate matter
			8	**Assay:** (by HPLC)
			9	Sterility
122.	NRD-221	Doxycycline for Injection USP 100 mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Organic Impurities (by HPLC)
			5	pH
			6	Average net Content
			7	Loss on drying
			8	Uniformity Of dosage unit
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
123.	NRD-228	Eribulin Inj. 0.5mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
124.	NRD-229	Eribulin Inj. 1 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
125.	NRD-230	Ertapenem sodium Inj. 1gm = Ertapenem 1.046 gm	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
126.	NRD-231	Etomidate Inj. USP 20 mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Organic Impurities (by HPLC) Related compound
			5	Total propylene glycol ester (by HPLC)
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
127.	NRD-236	Fluconazole Inj. USP 200 mg	1	Description
			2	Identification (by HPLC)
			3	Sodium Chloride Content (chemical)
			4	Organic Impurities (by HPLC) for Non Polar Impurities
			5	for Polar Impurities (by HPLC)
			6	Organic Impurities (by HPLC) procedure-3
			7	Organic Impurities (by HPLC) procedure-4
			8	Average net Content
			9	Uniformity Of dosage unit
			10	Extractable volume
			11	Particulate matter
			12	Bacterial endotoxins

			13	**Assay:** (by HPLC)
			14	Sterility
128.	NRD-237	Fludarabine Phosphate Injection IP 100mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Related substances (by HPLC)
			8	Becterial endotoxins
			9	Particulate matter
			10	Extractable volume
			11	Assay: (by HPLC)
			12	Sterility
129.	NRD-238	Fludarabine Phosphate Injection IP 50mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Related substances (by HPLC)
			8	Becterial endotoxins
			9	Particulate matter
			10	Extractable volume
			11	Assay: (by HPLC)
			12	Sterility
130.	NRD-242	Fondaparinux Sodium Inj. USP 2.5mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	Organic Impurities (by HPLC)
			5	Free Sulphate Determination (by HPLC)
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
131.	NRD-246	Fulvestrant Inj. 250mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
132.	NRD-249	Injection Goserelin Acetate implant 3.6 mg BP	1	Description
			2	Identification A (HPLC)
			3	Identification B: Size exclusion Chromatography
			4	Drug Release
			5	Related Substances (by HPLC)
			6	Acetic Acid(by GLC)
			7	Water
			8	Bacterial endotoxins
			9	Uniformity of Content (HPLC)
			10	Average Fill Volume
			11	Extractable volume
			12	Particulate matter
			13	Impurity
			14	**Assay: by** Size exclusion Chromatography
			15	Sterility
133.	NRD-263	Intralipds 10% Injection 10gm/100ml	1	Description
			2	Nominal Volume
			3	Extractable volume
			4	pH
			5	Globule Size (by Microscope)

			6	Peroxide Value
			7	Free Acid Value
			8	Bacterial endotoxins
			9	Assay
			10	Content of Long chain Triglycerides
			11	Content of Medium chain Triglycerides
			12	Glycerol
			13	Sterility
134.	NRD-264	Invert Sugar 10% Inj. IP	1	Description
			2	Identification
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	5-Hydroxymethylfurfural and Related substances (by UV)
			8	Bacterial endotoxins
			9	Particulate matter
			10	Extractable volume
				Heavy metals
				Chloride
				Completeness of inversion(by HPLC)
			11	Assay:
			12	Sterility
135.	NRD-265	Iohexol USP (solution for Injection) non Ionic contrast medium in sterile aqueous solution, 300 mg lodine/ml non ionic 50 ml	1	Description
			2	Identification (by HPLC)
			3	Organic impurities (by HPLC)
			4	Bacterial endotixins
			5	pH
			6	Particulate matter (by Liquid particle size analyzer)
			8	Free Iodide
			9	Uniformity Of dosage unit
			10	Sterility
			11	Extractable volume
			12	Assay (by chemical)
136.	NRD-271	Lacosamide Infusion 200mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
137.	NRD-274	Levosulpride Inj. 12.5 MG/ML 2ml	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
138.	NRD-278	Lignocaine Hydrochloride Inj. IP 2% 50ml vial	1	Description
			2	Identification A (Chemical)
			3	Identification B: Melting Point
			4	Identification C (Chemical)
			5	pH
			6	2,6-Dimethylaniline
			7	Bacterial endotoxins
			8	Nominal Volume
			9	Average Fill Volume
			10	Uniformity of Volume
			11	Particulate matter

			12	**Assay:** Lignocaine hydrochloride (by titration)
			13	Sterility
139.	NRD-285	Mephentermine 30mg/ml Inj. 10ml Vial IP	1	Description
			2	Identification A
			3	Identification B
				Identification C
				pH
			4	Average net Content
			5	Uniformity Of weight
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by Chemical)
			11	Sterility
140.	NRD-286	Meropenem Inj.IP 2gm	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	pH
			6	Related Substances (by HPLC)
			7	Content of Sodium (by FP/AAS)
			8	Bacterial endotoxins
			9	Loss on drying
			10	Clarity of solution test a and b
			11	Particulate matter
			12	**Assay:** (by HPLC)
			13	Sterility
141.	NRD-288	Methotrexate Inj. IP 250 mg	1	Description
			2	Identification (by UV)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Related substances (by HPLC)
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
142.	NRD-289	Methotrexate Inj. IP 1000 mg	1	Description
			2	Identification (by UV)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Related substances (by HPLC)
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
143.	NRD-290	Methylene Blue Inj. USP 10mg/ml	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Organic Impurities (by HPLC)
			5	Limit of Azure-B (by HPLC)
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
144.	NRD-291	Methylprednisolon Acetate Inj. IP 40mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Particulate matter
			8	Extractable volume
			9	Assay: (by HPLC)

			10	Sterility
145.	NRD-292	Methylprednisolon Acetate Inj. IP 125mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Particulate matter
			8	Extractable volume
			9	Assay: (by HPLC)
			10	Sterility
146.	NRD-294	Midazolam Inj. IP 5mg/ml 1 ml	1	Description
			2	Identification (by IR)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Related substances (by HPLC)
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
147.	NRD-295	Milrinone Lactate Inj. USP 10 MG	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Organic Impurities (by HPLC)
			5	Content of Lactic Acid (by HPLC)
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
148.	NRD-296	Mitomycin Inj. IP 2 mg	1	Description
			2	Identification (by TLC)
			3	pH
			4	Water
			5	Average net Content
			6	Uniformity Of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Bacterial endotoxins
			10	**Assay:** (by HPLC)
			11	Sterility
149.	NRD-297	Mitomycin Inj. IP 40 mg	1	Description
			2	Identification (by TLC)
			3	pH
			4	Water
			5	Average net Content
			6	Uniformity Of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Bacterial endotoxins
			10	**Assay:** (by HPLC)
			11	Sterility
150.	NRD-301	Moxifloxin Inj. 400mg/100ml	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
151.	NRD-303	Nabpaclitaxel Inj. (Paclitaxel Nano Particle)100 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight

			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
152.	NRD-304	Nandrolone Decanoate Inj. IP 100mg	1	Description
			2	Identification (by TLC)
			3	Average net Content
			4	Uniformity Of weight
			5	Particulate matter
			6	Extractable volume
			7	Assay: (by HPLC)
			8	Sterility
153.	NRD-305	Nandrolone Decanoate Inj. IP 50 mg	1	Description
			2	Identification (by TLC)
			3	Average net Content
			4	Uniformity Of weight
			5	Particulate matter
			6	Extractable volume
			7	Assay: (by HPLC)
			8	Sterility
154.	NRD-317	Octreotide Inj. 100mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
155.	NRD-318	Octreotide-LAR Inj. (long Acting Release) 20 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
156.	NRD-319	Octreotide-LAR Inj. (long Acting Release) 30 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
157.	NRD-322	Ornidazole Inj. IP 500mg	1	Description
			2	Identification (by HPLC)
			3	Appearance of Solution
			4	Related substances (by HPLC)
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
158.	NRD-323	Palonosetron Inj. 0.25mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)

			10	Sterility
159.	NRD-326	Peg Asparaginase Inj. 3750 IU 5 ml	1	Description
			2	Identification A by Fermentive activity
			3	Identification B by chemical test
			4	**Constituted solution**
			5	Completeness of solution
			6	Clarity of solution
			7	Colour of solution (UV)
			8	Uniformity of dosage unit (weight variation)
			9	Uniformity of weight
			10	Particulate matter by liquid particle size analyser
			11	By Visual inspection
			12	By light obscuration Particle Count test
			13	Average Net Content
			14	pH
			15	Bacterial endotoxins
			16	Sterility
			17	Water
			18	Reconstitution time
			19	Content of Amino acetic acid
			20	Content of Protein
			21	Fermentive activity
			22	Specific gravity
160.	NRD-330	Pemetrexed Inj.IP 100mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	**Assay:** (by HPLC)
			9	Sterility
161.	NRD-331	Pemetrexed Inj.IP 500 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	**Assay:** (by HPLC)
			9	Sterility
162.	NRD-335	Piperacillin 1 gm + Tazobactum 125 mg Inj. IP	1	Description
			2	Identification (by HPLC)
				Piperacillin
				Tazobactum
			3	pH
			4	Water
			5	Related Substances (by HPLC)
			6	Bacterial Endotoxins
			7	Average net content
			8	Uniformity of weight
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay: (by HPLC)**
				Piperacillin
				Tazobactum
			12	Sterility
163.	NRD-336	Piracetam 200mg Inj.	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter

			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
164.	NRD-338	Plerixafor Inj. 24 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
165.	NRD-340	Potassium Chloride 10% Injection IP	1	Description
			2	Identification
				Potassium
				Chloride
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Extractable volume
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:(Atomic absorption Spectrometery)**
			10	Sterility
166.	NRD-353	Risperidone prolonged released Depot/Suspernsion 25 mg Inj.	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
167.	NRD-354	Risperidone prolonged released Depot/Suspernsion 50mg Inj.	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
168.	NRD-361	Ropivacaine Inj. IP 0.75% 20ml vial	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by HPLC)
			4	Limit of Ropivacaine Related Compound (by HPLC)
			5	pH
			6	Enantiomeric Purity (by HPLC)
			7	Average net Content
			8	Uniformity Of weight
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	Assay:(by HPLC)
			13	Sterility
169.	NRD-364	Sildenafil Injection BP 0.8mg	1	Description
			2	Identification A (by TLC)
				Identification B: by HPLC
			4	Related substances (by HPLC)
			5	Average net content
			6	Uniformity of weight
			7	Particulate matter

			8	Extractable volume
			9	**Assay**: (by HPLC)
			10	Sterility
170.	NRD-365	Sodium Bicarbonate Inj. 7.5% IP Injection	1	Description
			2	Identification A (Chemical)
			3	Identification B (Chemical)
			4	PH
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	**Assay: (Chemical)**
			11	Sterility
171.	NRD-367	Sodium Hyaluronate Inj. 1.4mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
172.	NRD-371	Teicoplanin Inj. IP 200 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Appearance of Solution
			5	pH
			6	Composition and Related Substances (by HPLC)
			7	Average net Content
			8	Impurity -A (by HPLC)
			9	Chlorides
			10	Heavy metals
			11	Water
			12	Bacterial endotoxins
			13	Uniformity Of weight
			14	Clarity of solution test a and b
			15	Particulate matter
			16	**Assay:** (by Microbiological)
			17	Sterility
173.	NRD-372	Teicoplanin Inj. IP 400 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Appearance of Solution
			5	pH
			6	Composition and Related Substances (by HPLC)
			7	Average net Content
			8	Impurity -A (by HPLC)
			9	Chlorides
			10	Heavy metals
			11	Water
			12	Bacterial endotoxins
			13	Uniformity Of weight
			14	Clarity of solution test a and b
			15	Particulate matter
			16	**Assay:** (by Microbiological)
			17	Sterility
174.	NRD-379	Tigecycline for injection USP 50mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	pH
			5	Organic Impurities (by HPLC)
			6	Average net Content
			7	Bacterial Endotoxins
			8	Uniformity Of dosage unit
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay:** (by HPLC)
			12	Sterility

175.	NRD-380	Tigecycline for injection USP 100mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	pH
			5	Organic Impurities (by HPLC)
			6	Average net Content
			7	Bacterial Endotoxins
			8	Uniformity Of dosage unit
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay:** (by HPLC)
			12	Sterility
176.	NRD-381	Tobaramycin Inj. IP 80mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (Chemical)
			4	PH
				Related substances (by HPLC)
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by Microbiological)
			11	Sterility
177.	NRD-382	Topotecan Inj. IP 1 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			4	PH
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
178.	NRD-383	Topotecan Inj. IP 2.5 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			4	PH
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
179.	NRD-384	Topotecan Inj. IP 4 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			4	PH
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
180.	NRD-387	Trabectedin 1 mg Inj.	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b

			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
181.	NRD-393	Trypan Blue 0.06% w/v Inj.	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
182.	NRD-394	Triptorelin Inj. 0.1 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
183.	NRD-395	Triptorelin Inj.3.75 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
184.	NRD-396	Triptorelin Inj. 11.25 mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
185.	NRD-400	Vinorelbine Inj. IP 10mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	pH
			5	Light absorption (by UV)
			6	Related substances (by HPLC)
			7	Average net Content
			8	Uniformity Of weight
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
186.	NRD-401	Vinorelbine Inj. IP 50mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	pH
			5	Light absorption (by UV)
			6	Related substances (by HPLC)
			7	Average net Content
			8	Uniformity Of weight
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	**Assay:** (by HPLC)
			13	Sterility
187.	NRD-402	Vitamin D Inj. (600000 IU)	1	Description
			2	Identification (by HPLC)

			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	**Assay:** (by HPLC)
			10	Sterility
188.	NRD-410	lotion Asceptic (chlorhexadine gluconate 7.5% +15%cetrimide solution in 500ml bottle with dispenser)		As per STP of Firm
189.	NRD-411	Clotrimazole 1%+Beclomethasone Lotion 0.025%	1	Description
			2	Identification (by HPLC)
				Clotrimazole
				Beclomethasone
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
				Clotrimazole
				Beclomethasone
190.	NRD-412	Ketaconazole Lotion 2%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
191.	NRD-413	Minoxidil Lotion 2%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
192.	NRD-414	Minoxidil Lotion 5%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
193.	NRD-415	Minoxidil Lotion 10 %	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
194.	NRD-418	sunscreen Lotion SPF 30 (Octinoxate 7.5%,Avobenzone 2%, Oxybenzone 3%, Octocrylene 3% and Zinc Oxide 2%) 50ml		As per STP of Firm
195.	NRD-419	Clotrimazole Lozenges USP 10Mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by HPLC)
			6	Organic Impurity (by HPLC)
			7	Uniformity of Dosage unit
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
196.	NRD-421	Budesonide Inhalation IP 200 mcg.	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Average weight
			5	Epimer-A (by HPLC)
			6	Related Substances (by HPLC)
			7	Content of Active Ingredient delivered per actuation
			8	Uniformity of delivered dose
			9	Particle Size
			10	Number of deliveries per container
			11	leak test
			12	deposition of the emitted dose
			13	Contents of Packaged Dosage Forms
			14	**Assay:** (by HPLC)
197.	NRD-422	Formeterol 6mcg.+ Fluticasone 250 mcg.	1	Description

		Inhalation MDI	2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)
				Formetrol
				Budesonide
198.	NRD-423	Formoterol 6 mcg. + Budesonide 200 mcg. MDI IP	1	Description
			2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)
				Formetrol
				Budesonide
199.	NRD-424	Formoterol 6 mcg. + Budesonide 400 mcg. MDI IP	1	Description
			2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)
				Formetrol
				Budesonide
200.	NRD-425	Leosalbutamol 50mcg.+ Ipratopium 40mcg. MDI	1	Description
			2	Identification (by HPLC)
				Leosalbutamol
				Ipratopium
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)

				Leosalbutamol
				Ipratopium
201.	NRD-426	Levosalbutamol inhalation Solution 50mcg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	**Assay:** (by HPLC)
202.	NRD-429	Fluticasone propionate Nasal Spray IP 50mcg	1	Description
			2	Identification A (by TLC)
				Identification B(by HPLC)
				Related Substances (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	**Assay:** (by HPLC)
203.	NRD-431	Neomycin sulphate and Bacitracin Zinc ointment USP 5 mg + 500 IU/gm USP	1	Description
			2	Identification (by TLC)
				Neomycin sulphate
				Bacitracin
			3	Minimum Fill
			4	Water determination
			5	Uniformity of dosage unit
			6	Assay:
				Neomycin sulphate (microbial)
				Bacitracin (Chemical)
204.	NRD-432	Sodium Chloride Inj. IP 0.9% 3000ML(N.S)	1	Description
			2	Identification (Chemical)
			3	Heavy metals
			4	pH
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
			8	**Assay:** Sodium chloride (Chemical)
			9	Sterility
205.	NRD-433	Sodium Chloride Inj. 0.9% Biodegradable bag non DEHP 500ML	1	Description
			2	Identification (Chemical)
			3	Heavy metals
			4	pH
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
			8	**Assay:** Sodium chloride (Chemical)
			9	Sterility
206.	NRD-435	Clobetasol+Salicylic acid Ointment 0.5%+6%	1	Description
			2	Identification (by HPLC)
				Clobetasol
				Salicylic acid
			3	Contents of Packaged Dosage Forms
			4	**Assay: (by HPLC)**
				Clobetasol
				Salicylic acid
207.	NRD-437	Fluticasone Ointment IP 0.005%	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)

			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
208.	NRD-439	Tacrolimus Ointment 0 .03%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
209.	NRD-440	Tacrolimus Ointment 0 .1%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
210.	NRD-452	Bacillus Clausii Spores Suspension 2billion / 5ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
211.	NRD-453	Formeterol 20mcg +Budesonide 0.5mg Respiratory Solution/Suspension	1	Description
			2	Identification (by HPLC)
				Formeterol
				Budesonide
			3	Average net Volume
			4	Uniformity of volume
			5	**Assay:** (by HPLC)
				Formeterol
				Budesonide
			6	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
212.	NRD-454	Levosalbutamol 1.25 mg + Ipratropium 500 mcg Respiratory Solution 2.5 ml	1	Description
			2	Identification (by HPLC)
				Levosalbutamol
				Ipratropium
			3	Average net Volume
			4	Uniformity of volume
			5	**Assay:** (by HPLC)
				Levosalbutamol
				Ipratropium
			6	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	pH
			5	Related substances (by HPLC)
			6	Epimer A (by HPLC)
			7	Nominal Volume
			8	Uniformity of mass
			9	Uniformity of Dosage units
			10	**Assay:** (by HPLC)
			11	**Microbial Examination**
			12	Total aerobic microbial count
			13	Total combined yeast & moulds count

			14	Staphylococcus aureus
			15	Pseudomonas curuginesa
			16	Bile-tolerant gram-negative bacteria
214.	NRD-458	Glycopyrronium 25mcg. Inhalation Solution 2ml.	1	Description
			2	Identification (by HPLC)
			3	Average net Volume
			4	Uniformity of volume
			5	**Assay:** (by HPLC)
			6	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
215.	NRD-459	Sodium Chloride USP 3 %Respiratory solution	1	Description
			2	Identification A
				Sodium
				Chloride
			3	Identification B (by HPLC)
			4	Net Fill Weight
			5	pH
			6	Content Uniformity for premetered dosage form
			7	Foreign particulate matter
			8	**Assay:** (by HPLC)
			9	Sterility
216.	NRD-460	Tiotropium Bromide powder for Inhalation IP 18mcg	1	Description
			2	Identification (by HPLC)
			3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
			9	**Microbial Contamination**
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
217.	NRD-463	Fosfomycin Trometamol powder 3gm	1	Description
			2	Identification (by HPLC)
			3	Average net Content
			4	Uniformity Of weight
			5	Assay (by HPLC)
218.	NRD-465	L-Arginine 3gm and proanthocynadine 75mg granules	1	Description
			2	Identification (by HPLC)
				L-Arginine
				Proanthocynadine
				Disintegration Time
			3	Average net Content
			4	Uniformity Of weight
			5	Assay (by HPLC)
				L-Arginine
				Proanthocynadine
219.	NRD-467	Racecadotril Sachet IP 10 mg	1	Description
			2	Identification (by HPLC)
			3	Dissolution (by HPLC)
			4	Related substances (by HPLC)
			5	Average net Content
			6	Uniformity Of weight
			7	Assay (by HPLC)
220.	NRD-472	Mesalazine Suppository 500mg BP	1	Description
			2	Identification (by TLC)
			3	Related substances (by HPLC)
			4	Impurities A & C (by HPLC)
			5	Impurities K (by HPLC)

			6	Uniformity of dosage Units
			7	Disintegration Time
			8	**Assay:** (by HPLC)
221.	NRD-475	Cefaclor Oral Suspension IP Each 5 ml contain Cefaclor 125 Mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			6	Assay (by HPLC)
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
222.	NRD-476	Codiene Phosphate and Tripolidine Syrup (each 5ml contains Codiene Phosphate 10mg and Tripolidine 1.25mg)	1	Description
			2	Identification (by HPLC)
				Codiene Phosphate
				Tripolidine
				pH
				Water
			5	Contents of Packaged Dosage Forms
			6	Assay
				Codiene Phosphate
				Tripolidine
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
223.	NRD-477	Amlodipine oral solution BP 1 MG/ ML	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
				Identification of colour
			6	**Assay:** (by HPLC)
			7	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
224.	NRD-480	Baclofen Oral Solution IP 5 MG /ML	1	Description
			2	Identification A (by TLC)
				Identification B (by HPLC)
			3	Lactam (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
225.	NRD-481	Calcium Phosphate 200 ml Syrup (each 10ml contains elemental Calcium 300mg Elemental Phosphorus 150mg, Elemental Magnesium 75mg, Elemental Zinc 4mg, Vitamin D3 200-300IU)	1	As per STP of Firm
226.	NRD-486	Cefuroxime Axetil oral suspension BP 125mg/5ml	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Acidity and Alkanility
			5	Dissolution (by UV)
				Stability of Suspension (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
				Identification of colour

			8	**Assay:** (by HPLC)
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
227.	NRD-487	Clarithromycin for oral suspension USP 125mg/5ml	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Loss on drying
			5	Uniformity of dosage unit
			6	Deliverable Volume
			7	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			8	Assay (by HPLC)
			9	Identification of colour
			10	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
228.	NRD-488	Cefoperazone Inj. IP 1gm	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Clarity of solution test a and b
			10	Particulate matter
			11	**Assay:** (by HPLC)
			12	Sterility
229.	NRD-489	Cyclosporine Oral solution IP 100mg/ml	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Alcohol (by GLC)
			5	Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
230.	NRD-491	Cyproheptadine HCL 2mg/5ml Syrup IP	1	Description
			2	Identification (by UV)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay (by HPLC)
			6	Identification of colour
			7	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
231.	NRD-492	Dextromethorphan Hcl + Chlorpheniramine Syrup (each 5ml contains Dextromethorphane HBr 10mg and Chlorpheniramine 2mg)	1	Description
			2	Identification (by HPLC)
				Dextromethorphan
				Chlorpheniramine
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Dextromethorphan
				Chlorpheniramine
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli

232.	NRD-494	Drotavarine HCL 20mg/5ml Syrup/Suspension	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
233.	NRD-495	Milk of Magnesia 11.25 ml+ Liquid Paraffin 3.75 ml 170 ml Suspension Each 15 ml contains: Milk of Magnesia 11.25 ml+ Liquid Paraffin 3.75 ml 170 ml	1	Description
			2	Identification (by HPLC)
				Milk of Magnesia
				Liquid Paraffin
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Milk of Magnesia
				Liquid Paraffin
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
234.	NRD-496	Paracetamol 125 mg + Ibuprofen 100 mg 60 ml Suspension each 5 ml Containing : Paracetamol 125 mg + Ibuprofen 100 mg 60 ml	1	Description
			2	Identification (by HPLC)
				Ibuprofen
				Paracetamol
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Ibuprofen
				Paracetamol
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
235.	NRD-497	Enzyme 100 ML Syrup (each contains Diastase & Pepsin 10mg) 100ml	1	Description
			2	Identification (by HPLC)
				Diastase
				Pepsin
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Diastase
				Pepsin
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
236.	NRD-501	L-Carnitine 500mg/5ml in 30 ml USP	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Uniformity of dosage unit
			5	Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count

				Total fungal count
				E. coli
237.	NRD-503	Levofloxacin Oral Solution IP 125mg/5ml	1	Description
			2	Identification (by HPLC)
			4	pH
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
238.	NRD-504	Linezolid Oral Suspension/Syrup 100mg/5ml in 30ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
239.	NRD-505	Mefenamice Acid Suspension/Syrup 100mg/5ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
240.	NRD-508	Montelucast+Levocetrizine Oral Solution/Suspension Each ml contains Montelukast 4mg+Levocetrizine 2.5mg	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
241.	NRD-509	Nitrofurantoin oral suspension BP 25mg/5ml in 100ml	1	Description
			2	Identification A (by UV)
			3	Identification B (by chemical)
				Stability of Suspension (by HPLC)
			4	Contents of Packaged Dosage Forms
			5	**Assay:** (by Chemical)
				Identification of colour
			6	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	1	Description
			2	Identification A (by TLC)
				Identification B (by HPLC)
			4	pH
				Ondansetron Impurity-D (by HPLC)
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)

			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				Total Enterobacteriaceae
				E. coli
243.	NRD-512	Phenobarbitone 20mg/5ml in 100ml Syrup	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
244.	NRD-514	Piracetam Syrup/Suspension 500mg/5ml in 100ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
245.	NRD-515	Potassium & Magnesium citrate Oral Solution Each 5ml contains Potassium citrate 1100mg+Magnesium citrate 375mg	1	Description
			2	Identification (by HPLC)
				Potassium citrate
				Magnesium citrate
			3	Water
			4	pH
			5	Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
				Potassium citrate
				Magnesium citrate
			7	Identification of colour
			8	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
246.	NRD-516	Ranitidine oral Solution 75mg/5ml IP	1	Description
			2	Identification (by HPLC)
			4	pH
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
248.	NRD-519	Sodium Picosulphate Oral Solution 5mg/5ml BP	1	Description
			2	Identification A (by TLC)

			3	Identification (by HPLC)
			4	Impurity A (by HPLC)
			7	Contents of Packaged Dosage Forms
				Identification of colour
			8	**Assay:** (by HPLC)
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
249.	NRD-520	Sorbitol + Tricholine Citrate Syrup/Solution Each 10ml contains Sorbitol(70%) 7.15gm & Tricholine Citrate (66%) 0.55gm	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
250.	NRD-521	Sucralphate Oral Suspension/Syrup Each 5ml contains sucralphate 500mg	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
251.	NRD-522	Triclofos oral Solution 500 mg/ 5ml in 30ml	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Weight per ml
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by Chemical)
				Identification of colour
			7	**Microbial Examination**
				Total Aerobic Count
				Total fungal Count
				E. coli
252.	NRD-523	Ursodeoxycholic oral suspension BP 125mg/5ml 100ml Bottle	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by HPLC)
			4	pH
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
				Identification of colour
			8	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
			8	**Assay:** (by UV)
253.	NRD-524	Zinc Sulpate oral Solution IP 20 mg/5ml	1	Description
			2	Identification (by Chemical)
				Sulphates
				Zinc
			3	pH

			4	Weight per ml
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by Chemical)
				Identification of colour
			7	**Microbial Examination**
				Total Aerobic Count
				Total fungal Count
				E. coli
254.	NRD-525	Azithromycin oral suspension IP 100mg/5ml	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			6	**Assay:** (by HPLC)
				Identification of colour
			7	**Microbial Examination**
				Total Aerobic Count
				Total fungal Count
				E. coli
255.	NRD-526	Azithromycin oral suspension IP 200mg/5ml	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related substances (by HPLC)
				Stability of Suspension (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	**Assay:** (by HPLC)
				Identification of colour
			7	**Microbial Examination**
				Total Aerobic Count
				Total fungal Count
				E. coli
256.	NRD-527	Midodrine Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
257.	NRD-528	Hydroxyurea Cap. 500mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
258.	NRD-530	Everolimus Tab./Cap. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
259.	NRD-531	Everolimus Tab./Cap. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
260.	NRD-532	Tacrolimus Cap. IP 0.25mg	1	Description
			2	Identification (by HPLC)
			4	Average weight

			5	Uniformity of content (by HPLC)
			7	Dissolution (by HPLC)
				Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
261.	NRD-533	Nintedanib 150MG Tab./Cap.	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
262.	NRD-535	Acebrophylline SR Tab. 200 Mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
263.	NRD-536	Aceclofenac 100mg + Thiocolchicoside 4mg Tab.	1	Description
			2	Identification (by HPLC)
				Aceclofenac
				Thiocolchicoside
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Aceclofenac/Thiocolchicoside
			5	Uniformity of Weight
				Uniformity of Content (by HPLC) Thiocolchicoside 4mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Aceclofenac
				Thiocolchicoside
264.	NRD-537	Aceclofenac SR Tab. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
265.	NRD-538	Aceclofenac+Paracetamol+ Serratiopeptidase Tab. (100+325+15 mg)	1	Description
			2	Identification (by HPLC)
				Aceclofenac
				Paracetamol
				Serratiopeptidase
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Aceclofenac/Paracetamol/Serratiopeptidase
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Aceclofenac
				Paracetamol
				Serratiopeptidase
266.	NRD-539	Afatinib Tab. 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
267.	NRD-540	Afatinib Tab. 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight

			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
268.	NRD-541	Afatinib Tab. 40 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
269.	NRD-542	Alendronate Sodium Tab. IP 70 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				Phosphate and Phosphite (by HPLC)
				4-Aminobutanoic Acid (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
270.	NRD-543	Alfuzosin Tab. IP 10 mg	1	Description
			2	Identification A (by IR)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
271.	NRD-544	Alpelisib Tab. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
272.	NRD-545	Alpelisib Tab. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
273.	NRD-546	Alpelisib Tab. 250 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
274.	NRD-547	Amantidine Tab./Cap. 100mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
275.	NRD-548	Amisulpride Tab. IP 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
276.	NRD-549	Apixaban Tab. 2.5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight

			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
277.	NRD-550	Apixaban Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
278.	NRD-551	Aripiprazole Tab. IP 10 mg	1	Description
			2	Identification(by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related Substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
279.	NRD-552	Aripiprazole Tab. IP 5 mg	1	Description
			2	Identification(by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related Substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
280.	NRD-553	Aspirin Tab. IP 300 mg	1	Description
			2	Identification (by Chemical)
			3	Average weight
			4	Uniformity of weight
			5	Salicylic Acid
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by Chemical)
281.	NRD-555	Atomoxetin Tab. 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
282.	NRD-556	Atomoxetin Tab. 18 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
283.	NRD-557	Atomoxetin Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
284.	NRD-559	Axitinib Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
285.	NRD-560	Bilastin Tab. 20mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight

			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
286.	NRD-561	Biotin 5 MG Tab. USP	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of dosage unit
			5	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
287.	NRD-562	Bosentan Tab. IP 62.5 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
288.	NRD-564	Brivaracetam Tab. 50mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
289.	NRD-565	Buprenorphine Sublingual Tablet/Buprenorphine HCL Tablet 0.2mg	1	Description
			2	Identification A (by TLC)
				Identification B (by UV)
			3	Average Weight
				Related substances (by HPLC)
			4	Disintegration Time
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
290.	NRD-566	Calcium Acetate Tab. USP 667mg	1	Description
			2	Identification
				Calcium
				Acetate
			3	Limit of Aluminium (by Fluroscence Spectroscopy)
			4	Average Weight
			5	Dissolution (by AAS)
			6	Uniformity of dosage unit
			7	Contents of Packaged Dosage Forms
			8	Assay (by chemical)
291.	NRD-568	Capmatinib Tab. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
292.	NRD-569	Carbimazole Tab. IP 10 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (Chemical)
			4	Average weight
			5	Uniformity of content (by UV)
			6	Thiamazole and other related substances (by HPLC)
			7	Disintegration time
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
293.	NRD-570	Cefixime + Potassium Clavulanate Tab. 200+125mg	1	Description
			2	Identification (by HPLC)
				Cefixime
				Clavulanic Acid
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Cefixime/Clavulanic Acid

			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Cefixime
				Clavulanic Acid
294.	NRD-571	Cefpodoxime proxetil Tab. IP 100mg/ Cefpodoxime proxetil Dispersible Tab. 100mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
295.	NRD-572	Cefpodoxime Tab. IP 200mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
296.	NRD-573	Cefpodoxime CV 375 Tab.	1	Description
			2	Identification (by HPLC)
				Cefpodoxime
				Clavulanic Acid
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Cefpodoxime/Clavulanic Acid
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Cefpodoxime
				Clavulanic Acid
297.	NRD-574	Chlordiazepoxide Tab. IP 25 mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
				Related substances (by TLC)
			8	**Assay:** (by UV)
298.	NRD-575	Chlordiazepoxide 5 Mg + Clidinium 2.5 mg Tab.	1	Description
			2	Identification (by HPLC)
				Chlordiazepoxide
				Clidinium
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium
			5	Uniformity of Weight
				Unifromity of Content (by HPLC)
				Chlordiazepoxide 5 Mg
				Clidinium 2.5 mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Chlordiazepoxide
				Clidinium
299.	NRD-576	Chlorthalidone Tab. IP 6.25 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
				Identification C (by Chemical)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms

			9	**Assay:** (by UV)
300.	NRD-577	Colchicine Tab. IP 0.5mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
301.	NRD-578	Cilostazol Tab. IP 50mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
302.	NRD-579	Cilostazol Tab. IP 100mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
303.	NRD-580	Clarithromycin Tab. IP 250 MG	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
304.	NRD-581	Clarithromycin Tab. IP 500mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
305.	NRD-582	Cilnidipine Tab. IP 5 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
306.	NRD-583	Cilnidipine Tab. IP 10 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms

			8	**Assay:** (by HPLC)
307.	NRD-584	Cilnidipine Tab. IP 20 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
308.	NRD-585	Clonazepam Tab. IP 0.25	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
309.	NRD-586	Clonazepam Tab. IP 1Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
310.	NRD-587	Clozapine Tab. IP 25 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
311.	NRD-588	Clozapine Tab. IP 50 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
312.	NRD-589	Clozapine Tab. IP 100 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
313.	NRD-590	Co-trimoxazole Tablet IP 480mg (Trimethoprim 80mg+Sulphamethoxazole 400mg)	1	Description
			2	Identification A (by IR)
				Identification B (by IR)
			3	Identification C (by TLC)
			4	Average weight

			5	Uniformity of weight
			6	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
				Trimethoprim (by HPLC)
				Sulphamethoxazole (by HPLC)
314.	NRD-591	Cefuroxime Axetil Tab. IP 500 mg.	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
			10	Identification of colour
315.	NRD-592	Cyproheptadine Tab. IP 4Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Identification C (by Chemical)
			5	Average Weight
			6	Disintegration Time
			7	Related substances (by TLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
316.	NRD-593	Cyproterone Acetate 2 mg +Ethynil Estradiol 0.035mg Tab.	1	Description
			2	Identification (by HPLC)
				Cyproterone Acetate
				Ethynil Estradiol
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Cyproterone Acetate HCL/Ethynil Estradiol
			5	Uniformity of Content (by HPLC)
				Cyproterone Acetate
				Ethynil Estradiol
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Cyproterone Acetate
				Ethynil Estradiol
317.	NRD-594	Dabigatran Tab. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
318.	NRD-595	Dabigatran Tab. 110 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
319.	NRD-596	Dabrafenib Tab./Cap. 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
320.	NRD-597	Dacomitinib Tab. 15 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
321.	NRD-598	Dacomitinib Tab. 30 mg	1	Description

			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
322.	NRD-599	Dapagliflozin Tab. 10 MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
323.	NRD-600	Dapoxetine Tab. IP 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Uniformity of weight
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
324.	NRD-601	Dapsone Tab. IP 100 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Uniformity of weight
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by Chemical)
325.	NRD-602	Deflazacort Tab. 6mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
326.	NRD-603	Deflazacort Tab. 12 MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
327.	NRD-604	Desvenlafaxine Tab. 50mg CR/PR/SR/ER	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
328.	NRD-605	Diclofenac Sodium 50mg+ Paracetamol 325mg+ Serratiopeptidase 10mg Tab.	1	Description
			2	Identification (by HPLC)
				Diclofenac
				Serratiopeptidase
				Paracetamol
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Diclofenac/Serratiopeptidase/Paracetamol
			5	Uniformity of Weight
				Uniformity of Content (by HPLC) Serratiopeptidase 10mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Diclofenac
				Serratiopeptidase
				Paracetamol
329.	NRD-606	Diclofenac 50 mg and Thiocolchicoside 8	1	Description
			2	Identification (by HPLC)

		mg Tab.		Diclofenac
				Thiocolchicoside
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Diclofenac/Thiocolchicoside
			5	Uniformity of Weight
			6	Unifromity of Content (by HPLC) Thiocolchicoside 8 mg
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
				Diclofenac
				Thiocolchicoside
330.	NRD-608	Diltiazem CR/prolonged released Tab. BP 90mg	1	Description
			2	Identification A (by TCL)
				dentification B (by HPLC)
			3	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
331.	NRD-609	Dimethyl Fumarate Tab. 120 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
332.	NRD-610	Dimethyl Fumarate Tab. 240mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
333.	NRD-611	Disulfiram Tab. 500mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Identification C (by Chemical)
			5	Average Weight
			6	Diethyldithiocarbamate
			7	Disintegration Time
			8	Uniformity of weight
			9	Related substances (by TLC)
			10	Contents of Packaged Dosage Forms
			11	Assay (by UV)
334.	NRD-612	Disulfiram Tab. IP 250mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			5	Average Weight
			6	Diethyldithiocarbamate
			7	Disintegration Time
			8	Uniformity of weight
			9	Related substances (by TLC)
			10	Contents of Packaged Dosage Forms
			11	Assay (by UV)
335.	NRD-613	Donepezil Tab. IP 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Related substances (by HPLC)
			6	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
336.	NRD-614	Duloxetine gastro resistant Tab. IP 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)

				0.1M HCL
				Phosphate Buffer
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
337.	NRD-615	Duloxitine gastro resistant Tab. IP 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				0.1M HCL
				Phosphate Buffer
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
338.	NRD-616	Dydrogesterone Tab. IP 10mg	1	Description
			2	Identification A (by IR)
				Identification B (by HPLC)
			3	Average Weight
			4	Disintegration Time
				Related substances (by HPLC)
			5	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
339.	NRD-617	Eltrombopag Tab./Cap. 25MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
340.	NRD-618	Eltrombopag Tab./Cap. 50MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
341.	NRD-619	Empagliflazone Tab. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
342.	NRD-620	Empagliflazone Tab. 25mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
343.	NRD-621	Entacapone Tab. IP 200 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Uniformity of weight
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
344.	NRD-622	Erlotinib Tab. IP 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Uniformity of weight
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
345.	NRD-623	Erlotinib Tab. IP 100mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight

			4	Dissolution (by HPLC)
			5	Uniformity of weight
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
346.	NRD-624	Esomeprazole Gastro resistant Tab. IP 40 Mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				0.1M HCL
				Phosphate Buffer
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
347.	NRD-625	Estradiol Valerate Tab. 2 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
348.	NRD-627	Enzalupamide Tab./Cap. 40mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
349.	NRD-628	Ethynil Estradiol 0.02mg+ Desogestral 0.15mg Tab.	1	Description
			2	Identification (by HPLC)
				Ethynil Estradiol
				Desogestral
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Ethynil Estradiol/Desogestral
				Unifromity of Content (by HPLC)
				Ethynil Estradiol
				Desogestral
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Ethynil Estradiol
				Desogestral
350.	NRD-629	Etizolam Tab. IP 0.5 mg	1	Description
			2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg) Tab.	1	Description
			2	Identification (by HPLC)
				Etoricoxib
				Thiocolchicoside
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside
			5	Uniformity of Weight
				Unifromity of Content (by HPLC) Thiocolchicoside 8 mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Etoricoxib
				Thiocolchicoside
352.	NRD-632	Febuxostat Tab. 40 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms

			7	Assay (by HPLC)
353.	NRD-633	Febuxostat Tab. 80 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
354.	NRD-634	Fexofenadine Tab. IP 120 MG	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
355.	NRD-635	Fexofenadine Tab. IP 180 MG	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
356.	NRD-637	Fludrocortisone Tab. BP 100Mcg	1	Description
			2	Identification A (by TCL)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
357.	NRD-638	Flunarizine Tab. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
358.	NRD-639	Fluvoxamine Tab. IP 100 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
359.	NRD-640	Fluvoxamine Tab. IP 50 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
360.	NRD-643	Furosemide 20mg + Spironolactone 50mg Tab.	1	Description
			2	Identification (by HPLC)
				Furosemide
				Spironolactone
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)

				Furosemide/Spironolactone
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Furosemide
				Spironolactone
361.	NRD-644	Glucosamine hydrocloride 750mg + Diacerin 50 mg Tab.	1	Description
			2	Identification (by HPLC)
				Glucosamine hydrocloride
				Diacerin
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Glucosamine hydrocloride/Diacerin
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Glucosamine hydrocloride
				Diacerin
362.	NRD-645	Ibrutinib Tab. 140mg/Cap.	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
363.	NRD-646	Indomethacin Tab./Cap. 75 mg SR	1	Description
			2	Identification A (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1^{st} time point
				2^{nd} time point
				3^{rd} time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
364.	NRD-648	Ivabradine Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
365.	NRD-649	Ivermectin 6 mg + Albendazole 400 mg	1	Description
			2	Identification (by HPLC)
				Ivermectin
				Albendazole
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Ivermectin/Albendazole
			5	Uniformity of Weight
				Unifromity of Content (by HPLC) Ivermectin 6 mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Ivermectin
				Albendazole
366.	NRD-650	Ivermectin Tab. IP 6mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Limit of 8a-oxo-H2B1a
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
367.	NRD-651	Ivermectin Tab. IP 12mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Limit of 8a-oxo-H2B1a
			7	Contents of Packaged Dosage Forms

			8	Assay (by HPLC)
368.	NRD-652	Ketoconazole Tab. IP 200 mg	1	Description
			2	Identification A (by TLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
369.	NRD-653	Lacosamide Tab. BP 50 mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
				Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
370.	NRD-654	Lamotrigine Dispersible 100MG Tab. IP	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity Of Weight
			5	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
371.	NRD-655	Lapatinib Tab. IP 250mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity Of Weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
372.	NRD-656	Lenalidomide Tab. 25mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
373.	NRD-657	Lenalidomide Tab. 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
374.	NRD-658	Lenvatinib Tab. 4 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
375.	NRD-659	Lenvatinib Tab. 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
376.	NRD-660	Levetiracetam Tab. IP 250 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity Of Weight

			6	Dissolution (by HPLC)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
377.	NRD-662	Levodopa+Carbidopa+Entacapone 100mg/25mg/200mg Tab.	1	Description
			2	Identification (by HPLC)
				Levodopa
				Carbidopa
				Entacapone
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Levodopa/Carbidopa/Entacapone
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Tramadol
				Paracetamol
				Entacapone
378.	NRD-663	Levofloxacin Tab. IP 750 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
			9	Identification of colours
379.	NRD-665	Levothyroxine Sodium Tab. IP 25 mcg	1	Description
			2	Identification A
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Disintegration time
			8	**Assay: (**by HPLC)
380.	NRD-666	Levothyroxine Sodium Tab. IP 75 mcg	1	Description
			2	Identification A
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Disintegration time
			8	**Assay: (**by HPLC)
381.	NRD-668	Linaglipitin Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
382.	NRD-669	Lopinavir 200Mg+Ritonavir Tab. IP 50 mg	1	Description
			2	Identification (by HPLC)
				Lopinavir
				Ritonavir
			3	Average Weight
			4	Dissolution (by HPLC)
				Lopinavir
				Ritonavir
			5	Uniformity of Weight
				Related substances (by HPLC)
				Water
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Lopinavir
				Ritonavir

383.	NRD-670	Loratadine Tab. IP 10 mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Impurity- H (by GLC)
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
384.	NRD-671	Lorlatinib Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
385.	NRD-672	Lorlatinib Tab. 100 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
386.	NRD-673	Megestrol Acetate Tab. IP 160 mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of Weight
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by UV)
387.	NRD-674	Melatonin Tab. 3 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
388.	NRD-675	Melphalan Tab. IP 2mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
389.	NRD-678	Methimazole Tab. USP 10mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of Content (by UV)
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by Chemical)
390.	NRD-681	Methylphenidate Tab. 10 mg CR/PR/SR/ER	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
391.	NRD-682	Methylprednisolone Tab. IP 4mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)

			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
392.	NRD-683	Methylprednisolone Tab. IP 16mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of Weight
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
393.	NRD-684	Methylprednisolone Tab. IP 8mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
394.	NRD-686	Midostaurin Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
395.	NRD-687	Mirabegeron Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
396.	NRD-688	Mirabegeron Tab. 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
397.	NRD-689	Mirtazapine Tab. IP 7.5mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
398.	NRD-690	Mirtazapine Tab. IP 15mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
399.	NRD-692	Montelukast Tab. IP 4 mg	1	Description
			2	Identification (by HPLC)

			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
400.	NRD-693	Montelukast Tab. IP 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
401.	NRD-694	Montelukast Tab. IP 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
402.	NRD-695	Morphine Tab. IP 10mg	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of content (by HPLC)
			7	Related substances (by HPLC)
			8	Dissolution (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by Chemical)
403.	NRD-696	Morphine Tab. IP 30mg	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of weight
			7	Related substances (by HPLC)
			8	Dissolution (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by Chemical)
404.	NRD-697	Moxifloxacin Tab. BP 400 Mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
405.	NRD-698	Moxonidine Tab. BP 0.2 mg	1	Description
			2	Identification A (by TCL)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms

			8	**Assay:** (by HPLC)
406.	NRD-699	Moxonidine Tab. BP 0.3 mg	1	Description
			2	Identification A (by TCL)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
407.	NRD-700	N-Acetylecystine effervescent form, orange flavour, 600 mg Tab.	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
408.	NRD-701	Naltrexone Tab. IP 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of Weight
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
409.	NRD-702	Nebivolol Tab. IP 5mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
410.	NRD-703	Nebivolol Tab. IP 10mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
411.	NRD-704	Nicorandil Tab. IP 5mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
412.	NRD-705	Nicoumalone Tab. IP 1 Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (Chemical)
			5	Average weight
			6	Related substances (by TLC)
			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by UV)
413.	NRD-706	Nicoumalone Tab. IP 3 Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (Chemical)
			5	Average weight
			6	Related substances (by TLC)

			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by UV)
414.	NRD-707	Nicoumalone Tab. IP 4 Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (Chemical)
			5	Average weight
			6	Related substances (by TLC)
			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by UV)
415.	NRD-708	Nifidipine Cap. IP 10mg	1	Description
			2	Identification (by TLC)
			3	Average Weight
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of content (by UV)
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
416.	NRD-709	Nifidipine Tab. Prolonged Release IP 20mg	1	Description
			2	Identification (by TLC)
			3	Average Weight
			4	Dissolution (by UV)
				0.1M HCL
				Phosphate buffer
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
417.	NRD-710	Nilotinib Tab./Cap. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
418.	NRD-711	Nilotinib Tab./Cap. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
419.	NRD-712	Nilotinib Tab. 300mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
420.	NRD-713	Nitazoxanide Tab. 500mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
421.	NRD-714	Nitrazepam Tab. IP 5mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
422.	NRD-715	Nitrazepam Tab. IP 10 mg	1	Description

			2	Identification A (by UV)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
423.	NRD-716	Olaparib Tab. 100 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
424.	NRD-717	Olaparib Tab. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
425.	NRD-718	Olmesartan medoxomil Tab. IP 20mg	1	Description
			2	Identification A (by HPLC)
			4	Average Weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
426.	NRD-720	Osimertinib Tab. 80 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
427.	NRD-721	Oxcarbazepine Tab. IP 300MG	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
428.	NRD-722	Oxcarbazepine Tab. IP 450MG	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
429.	NRD-723	Oxazepam Tab. IP 15mg	1	Description
			2	Identification A (by IR)
				Identification B (by UV)
			3	Average Weight
			4	Disintegration Time
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
430.	NRD-725	Pantoprazole Gastro-resistant Tab. IP 20mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by HPLC)
				in 0.1 M HCL
				in tri-acetate buffer solution
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms

			8	Assay (by HPLC)
431.	NRD-726	Paracetomol Tab. IP 650 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by Chemical)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
432.	NRD-727	Paroxetine Control Release/Prolonged Release Tab. IP 12.5mg	1	Description
			2	Identification A (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
433.	NRD-728	Paroxetine Control Release/Prolonged Release Tab. IP 25mg	1	Description
			2	Identification A (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
434.	NRD-729	Pazopanib Tab./Cap. 200mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
435.	NRD-730	Pazopanib Tab./Cap. 400mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
436.	NRD-732	Pentoxifylline Extended Release/SR Tab. IP 400mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			6	Chromatographic Purity (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
437.	NRD-733	Perampanel Tab. 2 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
438.	NRD-734	Perampanel Tab. 4mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
439.	NRD-735	Pheniramine Tab. IP 25mg	1	Description

			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (by Chemical)
			5	Average Weight
			6	Disintegration Time
			7	Related substances (by TLC)
			8	Uniformity of Weight
			9	Contents of Packaged Dosage Forms
			10	Assay (by UV)
440.	NRD-737	Pirfenidone Tab. IP 200 mg	1	Description
			2	Identification A (by UV)
			3	Average Weight
			4	Disintegration Time
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
441.	NRD-738	Pirfenidone Tab. IP 400 mg	1	Description
			2	Identification A (by UV)
			3	Average Weight
			4	Disintegration Time
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
442.	NRD-739	Piroxicam DT 20mg Tab. IP	1	Description
			2	Identification A (by HPLC)
			4	Average weight
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
443.	NRD-740	Pomalidomide Tab. 2 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
444.	NRD-741	Pomalidomide Tab. 4 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
445.	NRD-742	Posacozazole 100mg Tab.	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
446.	NRD-743	Posacozazole oral Syrup 40mg/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	**Microbial Examination**
				Total aerobic count
				Total fungal count
				E. coli
447.	NRD-744	Prasugrel Tab. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms

			7	Assay (by HPLC)
448.	NRD-745 a	Prazosin Tab. IP 5mg	1	Description
			2	Identification A (by IR)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Related substances (by TLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
449.	NRD-745 b	Prazosin Tab. 5mg ER/PR/CR	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
450.	NRD-746	Prednisolone Tab. IP 40mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Related substances (by HPLC)
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
451.	NRD-747	Primidone Tab. BP 50 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by Chemical)
			4	2-Ethyl-2-phenylmalondiamide (by GLC)
			5	Average weight
			6	Uniformity of weight
			7	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by GLC)
452.	NRD-749	Prochlorperazine Tab. IP 5mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by Chemical)
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of Content (by HPLC)
			7	Related substances (by HPLC)
			8	Dissolution (by UV)
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by UV)
453.	NRD-750	Desogesterol 0.075mg Tab.	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
454.	NRD-751	Propranolol Tab. IP 10mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by UV)

455.	NRD-752	Propranolol Cap. 40 mg SR IP	1	Description
			2	Identification A (by UV)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
456.	NRD-755	Ranolazine Tab. 500MG ER/PR/CR	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
457.	NRD-756	Rasagiline Tab. 1mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
458.	NRD-757	Regorafenib Tab. BP 40 mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Impurity-A (by HPLC)
			5	Related substances (by HPLC)
			6	Average weight
			7	Uniformity of weight
			8	Dissolution (by UV)
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by HPLC)
459.	NRD-758	Repaglinamide Tab. 0.5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
460.	NRD-759	Repaglinamide Tab. 1mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
461.	NRD-760	Ribociclib Tab. 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
462.	NRD-761	Rifampicin Tab. IP 150 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
463.	NRD-762	Rifampicin Tab. IP 450 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by UV)

			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
464.	NRD-763	Rifampicin Tab. IP 600 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
465.	NRD-764	Rifaximin Tab. BP 200mg	1	Description
			2	Identification (by UV)
			3	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Water
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
466.	NRD-765	Rifaximin Tab. BP 550mg	1	Description
			2	Identification (by UV)
			3	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Water
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
467.	NRD-766	Rivaroxaban Tab. BP 10mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
468.	NRD-767	Rivaroxaban Tab. BP 15mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
469.	NRD-768	Rivaroxaban Tab. BP 20mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Impurity

			10	**Assay:** (by HPLC)
470.	NRD-769	Rizatriptan Tab. IP 10mg	1	Description
			3	Identification (by HPLC)
			4	Average Weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
471.	NRD-770	Ropinirole Tab. IP 0.25mg	1	Description
			3	Identification (by HPLC)
			4	Average Weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
472.	NRD-771	Rosuvastatin 10mg + Fenofibrate 160mg Tab. IP	1	Description
			2	Identification (by HPLC)
				Rosuvastatin
				Fenofibrate
			3	Average Weight
			4	Dissolution (by HPLC)
				Rosuvastatin
				Fenofibrate
			5	Uniformity of Content (by HPLC) Rosuvastatin
			6	Uniformity of weight
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
				Rosuvastatin
				Fenofibrate
473.	NRD-772	Ruxolitinib Tab./Cap. 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
474.	NRD-774	Ruxolitinib Tab./Cap. 15 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
475.	NRD-775	Ruxolitinib Tab./Cap. 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
476.	NRD-776	Selegiline Tab. IP 5mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	(S)-Selegiline (by HPLC)
			6	Disintegration Time
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
477.	NRD-777	Serratiopeptidase Tab. IP 10mg	1	Description
			2	Identification (by Chemical)
			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by Chemical)
478.	NRD-778	Serratiopeptidase Tab. IP 20 mg	1	Description
			2	Identification (by Chemical)

			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by Chemical)
479.	NRD-779	Sevelamer Carbonate Tab. 800 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
480.	NRD-780	Sildosin 8mg + Dutasteride 0.5mg Tab./Cap.	1	Description
			2	Identification (by HPLC)
				Sildosin
				Dutasteride
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Sildosin /Dutasteride
			5	Uniformity of Content (by HPLC)
				Sildosin
				Dutasteride
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Sildosin
				Dutasteride
481.	NRD-782	Sitagliptine Tab. 50 mg + Metformin Tab. 500mg	1	Description
			2	Identification (by HPLC)
				Sitagliptine
				Metformin
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Sitagliptine /Metformin
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Sitagliptine
				Metformin
482.	NRD-783	Sildenafil Tab. IP 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by UV)
				Related substances (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
483.	NRD-784	Sofosbuvir 400 mg+ Velpatasvir 100 mg Tab.	1	Description
			2	Identification (by HPLC)
				Sofosbuvir
				Velpatasvir
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Sofosbuvir/Velpatasvir
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Sofosbuvir
				Velpatasvir
484.	NRD-785	Solifenacin succinate Tab. IP 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				Related substances (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
485.	NRD-786	Sorafenib Tab. IP 200 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				Related substances (by HPLC)

			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
486.	NRD-788	Sunitinib Tab. 12.5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
487.	NRD-789	Sunitinib Tab.25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
488.	NRD-790	Sunitinib Tab.50 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
489.	NRD-791	Tacrolimus Tab./Cap. 1mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
490.	NRD-792	Tamsulosin HCL 0.4mg + Dutasteride 0.5mg Tab./Cap.	1	Description
			2	Identification (by HPLC)
				Tamsulosin HCL
				Dutasteride
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Tamsulosin HCL/Dutasteride
			5	Uniformity of Content (by HPLC)
				Tamsulosin HCL
				Dutasteride
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Tamsulosin HCL
				Dutasteride
491.	NRD-793	Tapentadol Tab. 50mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
492.	NRD-794	Tegafur 100mg + Uracil 224 mg Cap.	1	Description
			2	Identification (by HPLC)
				Tegafur
				Uracil
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Tegafur/Uracil
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Tegafur
				Uracil
493.	NRD-795	Tenofovir Tab. 300mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
494.	NRD-796	Tetrabenazine Tab. 25mg	1	Description

			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
495.	NRD-797	Ticagrelor Tab./Cap. BP 90mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	**Assay:** (by HPLC)
496.	NRD-798	Tofacitinib Tab. 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
497.	NRD-799	Tolvapatan Tab. 15mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
498.	NRD-800	Topiramate Tab. IP 50MG	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Related substances (by HPLC)
			6	Uniformity of weight
			7	Dissolution (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	**Assay:** (by HPLC)
499.	NRD-801	Torsemide Tab. IP 20mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Related substances (by HPLC)
			5	Uniformity of weight
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
500.	NRD-802	Tramadol 37.5mg + Paracetamol 325mg Tab.	1	Description
			2	Identification (by HPLC)
				Tramadol
				Paracetamol
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Tramadol/Paracetamol
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Tramadol
				Paracetamol
501.	NRD-803	Trametinib 0.5mg Cap.	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC) Trametinib
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
502.	NRD-804	Trimetazidine Tab. IP 35mg	1	Description

			2	Identification A (by HPLC)
				Identification B (by Chemical)
			3	Average Weight
			4	Dissolution (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
503.	NRD-805	Trimetazidine Modified release Tab. CR/PR/SR 60mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1st time point
				2nd time point
				3rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
504.	NRD-806	Trypsin 48mg + Rutoside 100mg +Bromelain 90mg tab.	1	Description
			2	Identification (by HPLC)
				Trypsin
				Rutoside
				Bromelain
			3	Average Weight
			4	Disintegration time/Dissolution (by HPLC) Trypsin/Rutoside/Bromelain
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Trypsin
				Rutoside
				Bromelain
505.	NRD-807	Trypsin & Chymotripsin Tab. (Each enteric coated tab. Contains 1 lakhs unit of enzymetic activity)	1	Description
			2	Identification (by HPLC)
				Trypsin
				Chymotripsin
			3	Average Weight
			4	Dissolution (by HPLC) Trypsin/Chymotripsin
				Acidic medium
				Phosphate medium
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Trypsin
				Chymotripsin
506.	NRD-808	Ulipristal Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
507.	NRD-809	Voriconazole Tab. IP 200 mg	1	Description
			2	Identification A (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
508.	NRD-812	Vildagliptin Tab. IP 50mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
509.	NRD-813	Voglibose Tab. IP 0.2 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Content (by HPLC)

			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
510.	NRD-814	Voglibose Tab. IP 0.3 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
511.	NRD-815	Warfarin Tab. IP 1MG	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
512.	NRD-816	Warfarin Tab. IP 2MG	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
513.	NRD-817	Warfarin Tab. IP 3MG	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
514.	NRD-818	Zinc Tab. 50MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
515.	NRD-819	Zolpidem Tab. IP 10mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
516.	NRD-820	Zonisamide Tab. 50mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
517.	NRD-821	Zonisamide Tab. 100 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
518.	NRD-822	Tiotropium 9mcg Inhalation	1	Description
			2	Identification (by HPLC)
			4	Average weight
			5	Content of Active Ingredient delivered per actuation
			6	Uniformity of delivered dose

			7	Particle Size
			8	Number of deliveries per container
			9	leak test
			10	deposition of the emitted dose
			11	Contents of Packaged Dosage Forms
			12	**Assay:** (by HPLC)
519.	697	Tab. Ketorolac 10 mg, IP	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Disintegration test
			5	Uniformity of Dispersion
			6	Uniformity of content (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
520.	702	Tab Divalproex Extended Release IP 250 mg (Each Extended Release Film Coated Tablet contains Divalproex Sodium IP Equivalent to Valproic acid 250 mg)	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	**Dissolution:**
				1st stage
				2nd stage
				3rd stage
				4th stage
				Related Substances (by GC)
			6	Contents of Packaged Dosage Forms
			7	**Assay:** (by HPLC)
521.	704	Tab. Lacosamide 100 mg (Each Film Coated Tablet contains Lacosamide 100 mg)	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of dosage unit
			5	Organic Impurities (By HPLC)
				Contents of Packaged Dosage Forms
			6	Dissolution (by HPLC)
			7	Assay: (by HPLC)
522.	708	Inj. Ceftriaxone 1 gm + Tazobactum 1.25 gm	1	Description
			2	**Identification of:**
				Ceftriaxone (by HPLC)
				Tazobactum (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	**pH**
			6	**Water**
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Bacterial endotoxins
			10	**Assay:**
				Ceftriaxone (by HPLC)
				Tazobactum (by HPLC)
			11	Sterility
523.	709	Tab. Cefadroxil 250 mg	1	Description
			2	Identification (by TLC)
			3	Average weight
			4	Uniformity of weight
			5	Uniformity of Dispersion
			6	Disintegration test
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
524.	713	Tab. Faropenem Sodium 200 mg (Each Film coated Tablet contains Faropenem Sodium equivalent to Faropenem Sodium 200 mg)	1	Description
			2	Identification (by UV)
			3	Average weight
			4	Uniformity of dosage Unit (Content Uniformity)
			5	Related Substances (by HPLC)
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
525.	722	Tab. Valganciclovir 450 mg	1	Description

			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Uniformity of dosage Unit (Content Uniformity)
			5	Organic Impurities (By HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	**Assay:** (by HPLC)
526.	738	Capsule Mycophenolate mofetil USP 250 mg (Each Capsule Contain Mycophenolate mofetil USP 250 mg)		**Mycophenolate mofetil Capsules IP**
			1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average net content
			6	Uniformity of weight
			7	Related substances (by HPLC)
			9	Dissolution (by HPLC)
			10	Water
			11	Contents of Packaged Dosage Forms
			12	**Assay:** (by HPLC)
527.	740	Tab. Mycophenolate Sodium 360 mg (Each Enteric Coated tablet Contain Mycophenolate Sodium 360 mg)	1	Description
			2	Identification (by HPLC)
			3	Identification (by UV)
			4	Average weight
			5	Uniformity of content (by HPLC)
			6	Disintegration test /Dissolution (By UV)
			9	Contents of Packaged Dosage Forms
			10	**Assay:** (by HPLC)
528.	NE25	Moxifloxacin Tablets 400mg	1	Description
			2	Identification A (by TLC)
				Identification B (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Related substances (by HPLC)
			8	**Assay:** (by UV)

Note:- Tablet /Capsules/Solution/Suspension/Syrup are different dosage forms and Testing Parameters may vary as per their Dosage form.

ANNEXURE –VIII
Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of insects and rodents besides cross contaminations ;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks, and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is provided & also unities like water, power and gas ;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes, thermometers etc. shall be thoroughly checked for accuracy for calibration before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be carried out in a fume cupboard	

Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a label.	
2	A standardization register shall be maintained, with its raw date and SOP for preparation and standardization on stock solutions, standard solutions and volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner considering the physicochemical properties substances and the hazard involved in their use.	
5	General and specific written down instructions for safety shall be circulated to each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves and face masks and eye protection wherever required	
9	The laboratories shall have adequate firs aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions - 1- water showered 2- Rubber suction bulbs must be used on manual and siphons ; 3- Warnings, precautions and written Instructions violent, uncontrollable or reactions. 4- Appropriate facilities for the collection, storage and disposal of wasters. 5- Safe disposal of corrosive or dangerous products by neutralization or deactivation. 6- Safety precautions to be adopted while handling potassium cyanide and bromide ; 7- SOP for handing, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

S.N.	Details of the requirement	Remark
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	

3	Reference material shall be traceable to agency authorized by Government of India or any other International body.	
4	The laboratory shall prepare working standard by comparing with the reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following details are to be written - a- Source of supply ; b- Code number of the reference material ; c- Date of receipt ; d- Batch number or identification number of the supplying agency ; e- Details like assay value, water content or information provided ; f- Storage condition of the material ; g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia requirements and the method demonstrably based on validation protocols are followed.	
2	Remedial action o the observations by internal and external audits are taken appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being conducted which includes test system, the type of analysis , date on which analysis is done	
7	Review yearly 1- Report or input 2- Matter arising from previous reviews ; 3- Report of external audits, if any ; 4- Surveillance report, if any ; 5- Result of proficiency testing ; 6- Complaints or feedback received from users 7- Details of in-house quality control checks ; 8- Need of amendment of the quality system and documentation ; 9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	Standard Operation Procedures for the followings are required (i) Sample handling and accountability ; (ii) Receipt identification, storage, mixing and method sampling of the test	

S.N.	Details of the requirement	Remark
	and control articles ; (iii) Record keeping, reporting, storage and retrieval of data ; (iv) Coding of different studies, handling of data including use of computerized data system : (v) Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews ; (vi) Routing inspection of cleaning maintenance, testing, calibration and standardization of instruments ; (vii) Action to be taken in respect of equipment failure ; (viii) Analytical data methods (ix) Health and safety protection ; (x) Date handling and storage retrieval ; (xi) Health and safety protection ; (xii) Animal room preparations ; (xiii) Animal care ; (xiv) Storage and maintenance of microbial cultures ; (xv) Maintenance of sterility room (i.e. constant maintenance and monitoring of Aseptic condition room) ; (xvi) Use and storage of reference standards ; (xvii) Procurement of stores and equipment ; (xviii) Monitoring of testing of samples ; (xix) Method of retention of unexpended samples, their location, maintenance and disposal ; (xx) Document control ; (xxi) Redressal of technical complaints ; (xxii) House- keeping (xxiii) Corrective and preventive action ; (xxv) Calibration manual. (xxvi) Training manual.	
4	Protocols and specification archive :- List of all the pharmacopeias a file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. The test methods shall be submitted to the concerned Drug Control Authority.	
5	Raw data - Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.	
6	Storage and archival ; The residual sample shall be retained in proper storage condition for a period of one year after the final report.	
7	The laboratory must establish and maintain procedures for the identification collection, indexing, retrieval, storage, maintenance, and Disposal of all quality documents.	
8	All the raw date, documentation, SOP, protocols and final reports are the be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure	

S.N.	Details of the requirement	Remark
	their security and confidentiality.	
10	Raw data on thermal paper might fad away with time ; therefore, a photocopy of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature:
Name of the Lab:
Date:
Official Seal:

ANNEXURE –IX
Ref: Clause no. 9 (2)

AGREEMENT

This Deed of Agreement is made on this _____day of_____ 2022 by M/s._____ represented by its Proprietor/ Managing partner /Managing Director having its laboratory Premises at _____ (hereinafter referred to as "Service provider" which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Whereas the Service provider has agreed to test the Drugs and Medicines for RMSC with specifications mentioned in the Schedule attached here to and mentioned at the prices noted there

in and in the manner and under the terms and conditions here in after mentioned and where as the Service provider has deposited with the Purchaser a sum of Rs_____(Rupees only) as Performance Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Service provider failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Service provider and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions including amendments contained in the invitation to tender floated for the Empanelment of Analytical Testing Laboratories for the test and Analysis of Drugs for Rajasthan Medical Services Corporation Ltd F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :- 27.07.2022, the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

1. (a) The Agreement is for the test by the Service provider to the Purchaser of the testing of Drug and Medicines specified in the Schedule attached here to at process noted against each therein on the terms and conditions set forth in the Agreement.

   (b) The Agreement with empanelled laboratories will remain valid up to 31.08.2024. This may be further extended for a further period of three months with mutual consent.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1. (a) In case the Service provider fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Service provider as Performance Security and cancel the Contract.

   (b) In case the Service provider fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Service provider under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Service provider as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Service provider having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Service provider to the Purchaser, either in his Tender or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Service provider. The Service provider will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

SERVICE PROVIDER NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Service provider shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Service provider give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Service provider permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SERVICE PROVIDER

5. In case the Service provider at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SERVICE PROVIDER

6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Service provider if delivered to him or left at his premises, place of business or abode.
7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SERVICER PROVIDER **(Signature, Name & Full Address)**	**Executive Director (Procurement),** **RAJASTHAN MEDICALSERVICES CORPORATION LTD.**

Witness (Signature, Name & Full Address)

1.

2.